[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 398
6. Tanaka K, Sasayama T, Kawamura A, Kondoh T, Kanomata N, Kohmura E: Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion. Neurol Med Chir (Tokyo); 2006 Apr;46(4):198-201
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion.
  • A 30-year-old man presented with a supratentorial malignant glioma manifesting as isolated progressive left oculomotor nerve paresis.
  • Computed tomography and magnetic resonance imaging showed an intra-axial tumor in the left temporal lobe, extending to the basal and prepontine cisterns, and compressing the brainstem.
  • The tumor was removed subtotally.
  • The histological diagnosis was anaplastic astrocytoma.
  • Malignant glioma with exophytic growth in the temporal lobe should be considered in the differential diagnosis of isolated oculomotor nerve paresis.
  • [MeSH-minor] Adult. Astrocytes / pathology. Biomarkers, Tumor / analysis. Brain Stem / pathology. Cerebral Arteries / pathology. Cisterna Magna / pathology. Dominance, Cerebral / physiology. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Nerve Compression Syndromes / diagnosis. Nerve Compression Syndromes / etiology. Nerve Compression Syndromes / pathology. Nerve Compression Syndromes / surgery. Neuronavigation. Oculomotor Nerve / pathology. Oculomotor Nerve / surgery. Pons / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636512.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Palani M, Arunkumar R, Janardhanam VA: Biochemical and cytogenetic analysis of brain tissues in different grades of glioma patients. Ann Neurosci; 2010 Jul;17(3):120-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical and cytogenetic analysis of brain tissues in different grades of glioma patients.
  • BACKGROUND: Glioma, a neoplasm of neuroglial cells, is the most common type of brain tumor, constituting more than 50% of all brain tumors.
  • PURPOSE: This report summarizes the current knowledge regarding the clinical utility of biochemical enzyme markers for both diagnostic and therapeutic purposes in different grades of glioma.
  • METHODS: Sixty patients with different grades of glioma include glioblastoma multiforme (n=20), Anaplastic astrocytoma (n=10).
  • CONCLUSION: The clinical importance for classification and treatment of glioma is governed by biochemical enzyme markers.
  • The study of enzymes supported by related chromosomal changes is anticipated to provide better appreciation of biological properties in different grades of glioma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25205887.001).
  • [ISSN] 0972-7531
  • [Journal-full-title] Annals of neurosciences
  • [ISO-abbreviation] Ann Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4116979
  • [Keywords] NOTNLM ; Antioxidants / Biochemical profile in glioma / Chromosomal aberrations / Enzymes / Glioma
  •  go-up   go-down


8. Molina Saera J, Segura Huerta A, Palomar Abad L, Giménez Ortiz A, Ponce Lorenzo J, Reynés Muntaner G: [Extra-cranial anaplastic oligoastrocytoma development from a low-grade glioma]. Clin Transl Oncol; 2005 Apr;7(3):127-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extra-cranial anaplastic oligoastrocytoma development from a low-grade glioma].
  • [Transliterated title] Afectación extracraneal de oligoastrocitoma anaplásico desarrollado sobre un glioma de bajo grado.
  • Oligodendrogliomas are primary brain tumours derived from oligodendroglial cells, or precursors, and represent 2%-5% of brain tumours.
  • This type of glioma has a favourable prognosis compared to other brain tumours.
  • We present a patient who had received treatment previously for a lowgrade glioma and who subsequently developed an anaplastic oligoastrocytoma in the same zone together with skull and extra-cranial involvement in the disease progression.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Glioma / surgery. Neoplasms, Second Primary / pathology. Skull Neoplasms / pathology. Temporal Bone. Temporal Lobe

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899221.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. Fountaine T, Lind CR, Law AJ: Primary glioblastomas and anaplastic astrocytoma in a glioma family. J Clin Neurosci; 2006 May;13(4):497-501
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary glioblastomas and anaplastic astrocytoma in a glioma family.
  • A 72-year-old man presented with a short duration of symptoms relating to a right fronto-parietal glioblastoma and a family history of children with brain tumours.
  • Analysis of the patient's family tree revealed that out of seven children, he had a living son with anaplastic astrocytoma, a daughter who had died with a glioblastoma, and a son who had died with a histologically undiagnosed intrinsic brain tumour.
  • One niece was also thought to have died from a brain tumour.
  • There is no clinical evidence to support a diagnosis of a multiple cancer or neurocutaneous syndrome in this family.
  • In view of what is known about the genetics of familial glioma, it is interesting to note the clinical evidence of both 'primary' glioblastoma and anaplastic astrocytoma in the same kindred.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Family Health. Glioblastoma / genetics

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16678736.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


10. Wick W, Weller M: Classification and management of anaplastic gliomas. Curr Opin Neurol; 2009 Dec;22(6):650-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification and management of anaplastic gliomas.
  • PURPOSE OF REVIEW: To summarize findings, discuss problems and define new questions from the past phase III trials in anaplastic gliomas.
  • RECENT FINDINGS: The current standard of care for first-line treatment in anaplastic gliomas is radiotherapy or chemotherapy.
  • Further, the notion that all anaplastic oligodendroglial tumors with or without a relevant astrocytic component fall into the same prognostic category and the obvious difficulties to type and to grade anaplastic gliomas pose an enormous burden on local diagnosis.
  • SUMMARY: Anaplastic gliomas are an important group of brain tumors to develop future molecularly targeted therapies and should therefore be in the main focus of academic and industrial drug development, which aims at efficacy and avoiding long-term side effects.
  • [MeSH-major] Brain Neoplasms. Glioma

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19770657.001).
  • [ISSN] 1473-6551
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


11. Mineo JF, Bordron A, Baroncini M, Maurage CA, Ramirez C, Siminski RM, Berthou C, Dam Hieu P: Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol; 2007 Dec;85(3):281-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.
  • We compared the HER2 expression in de novo GBM and in GBM resulting from anaplastic transformation of low-grade glioma ("secondary GBM").
  • [MeSH-major] Brain Neoplasms / metabolism. Cell Transformation, Neoplastic / metabolism. Glioblastoma / metabolism. Glioma / metabolism. Receptor, ErbB-2 / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571214.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


12. Ehsani S, Hodaie M, Liebsch NJ, Gentili F, Kiehl TR: Anaplastic glioma after high-dose proton-photon radiation treatment for low-grade skull base chondrosarcoma. J Neurooncol; 2008 Jun;88(2):231-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic glioma after high-dose proton-photon radiation treatment for low-grade skull base chondrosarcoma.
  • We report the case of a 63-year-old man who developed an anaplastic oligoastrocytoma of the brain stem and midbrain 13 years after postoperative high-dose proton-photon radiation therapy for a recurrent low-grade chondrosarcoma of the skull base.
  • To our knowledge, this is the first reported case of an anaplastic glioma after proton-photon irradiation.
  • [MeSH-major] Brain Stem Neoplasms / etiology. Chondrosarcoma / radiotherapy. Glioma / etiology. Photons / adverse effects. Skull Base Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18345517.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Synaptophysin
  •  go-up   go-down


13. Wick W, Weller M: [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts]. Nervenarzt; 2010 Aug;81(8):928-30, 932-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].
  • According to the current WHO classification anaplastic gliomas comprise pure astrocytomas and oligodendrogliomas and mixed tumors.
  • This review summarizes findings, discusses problems and defines new questions from the phase III trials on anaplastic gliomas.
  • Therefore, marker profiles should be included into the next WHO brain tumor classification.
  • The current standard of care for first-line treatment in anaplastic gliomas is radiotherapy or chemotherapy.
  • Furthermore, anaplastic gliomas are an important group of brain tumors for developing future molecular targeted therapies and should therefore be in the main focus of academic and industrial drug development, which aims at improved efficacy and avoiding long-term side-effects.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Brain / pathology. Chromosome Deletion. Clinical Trials as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Cranial Irradiation. DNA Modification Methylases / genetics. DNA Mutational Analysis. DNA Repair Enzymes / genetics. Disease-Free Survival. Humans. Isocitrate Dehydrogenase / genetics. Promoter Regions, Genetic / genetics. Survival Rate. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2009 May;10 (5):459-66 [19269895.001]
  • [Cites] J Neurol. 2009 May;256(5):734-41 [19240962.001]
  • [Cites] Science. 2009 Apr 10;324(5924):261-5 [19359588.001]
  • [Cites] Cancer Res. 2009 May 15;69(10 ):4502-9 [19366800.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1210-6 [18248979.001]
  • [Cites] J Neurooncol. 2009 May;92(3):401-15 [19357966.001]
  • [Cites] J Clin Oncol. 2010 Apr 20;28(12 ):2051-7 [20308655.001]
  • [Cites] Nat Rev Neurol. 2010 Jan;6(1):39-51 [19997073.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):392-401 [16648043.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] Neuro Oncol. 2008 Dec;10 (6):1019-24 [18676355.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5881-6 [19901104.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1963-72 [20231676.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):737-46 [19224764.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Cell. 2010 May 18;17(5):510-22 [20399149.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14 (21):7068-73 [18981004.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):257-9 [11958379.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]
  • [Cites] Acta Neuropathol. 2009 Oct;118(4):469-74 [19554337.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):330-5 [18240930.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Neurology. 2006 Jan 24;66(2):239-42 [16434662.001]
  • (PMID = 20635074.001).
  • [ISSN] 1433-0407
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


1
Advertisement
4. Passone E, Pizzolitto S, D'Agostini S, Skrap M, Gardiman MP, Nocerino A, Scarzello G, Perilongo G: Non-anaplastic pleomorphic xanthoastrocytoma with neuroradiological evidences of leptomeningeal dissemination. Childs Nerv Syst; 2006 Jun;22(6):614-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-anaplastic pleomorphic xanthoastrocytoma with neuroradiological evidences of leptomeningeal dissemination.
  • CASE REPORT: A case of a non-anaplastic pleomorphic xanthoastrocytoma (PXA) presenting with leptomeningeal dissemination (LMD) affecting a 9-year-old girl is presented.
  • In a 5-year period, the tumour underwent malignant transformation, bringing the child to death because of the primary tumour progression.
  • CONCLUSION: To our knowledge, this is the first case of a non-anaplastic PXA presenting with disseminated disease.
  • Thus, it was thought important to describe this case in order to add further information regarding the spectrum of the presenting clinical features of this rare neoplasm and the phenomenon of LMD of non-malignant glioma.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Meningeal Neoplasms / complications. Neoplasm Recurrence, Local / etiology

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369851.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


15. Hyder DJ, Sung L, Pollack IF, Gilles FH, Yates AJ, Davis RL, Boyett JM, Finlay JL: Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J Neurooncol; 2007 May;83(1):1-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience.
  • PURPOSE: To review interpathologist diagnosis variability and survival of children treated for either anaplastic mixed glioma (AMG) or anaplastic oligodendroglioma (AO) with surgery, irradiation and chemotherapy.
  • PATIENTS AND METHODS: Two hundred and fifty patients with an institutional diagnosis of malignant glioma were enrolled on Children's Cancer Group CCG-945 between 1985 and 1991, and administered vincristine during involved field radiotherapy, then six cycles of prednisone, lomustine and, vincristine; or two cycles of "eight-drugs-in-one-day" (8-in-1) chemotherapy then involved-field radiotherapy followed by six cycles of 8-in-1 chemotherapy.
  • Complete resection and cerebral tumor location was associated with better overall survival (OS) in patients with institutional diagnoses of AMG.
  • However, central review established that only nine of 26 children had AMG: either mixed oligoastrocytoma (MOA) or anaplastic mixed oligoastrocytoma (AOA) and only one had AO.
  • CONCLUSION: Diagnosis of these tumors is challenging, with only 35% of institutional diagnoses confirmed for AMG and 25% for AO, and survival among children with these tumors is poor, despite intensive therapy.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy. Oligodendroglioma / diagnosis. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Child. Child, Preschool. Cohort Studies. Drug Therapy. Female. Humans. Infant. Male. Neurosurgical Procedures. Radiotherapy. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / therapy. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252186.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  •  go-up   go-down


16. Green RM, Cloughesy T, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB: Bevacizumab for recurrent ependymoma. J Clin Oncol; 2009 May 20;27(15_suppl):2060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2060 Background: Ependymoma is a rare type of glioma, representing less than 5% of brain tumors in adults.
  • Therefore, we treated patients with recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens.
  • METHODS: We retrospectively identified adults treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964675.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Siker ML, Chakravarti A, Mehta MP: Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Crit Rev Oncol Hematol; 2006 Nov;60(2):99-111
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?
  • Malignant gliomas are devastating tumors associated with poor prognosis.
  • While it seems intuitive to apply this regimen to patients with anaplastic gliomas which have traditionally been considered more chemosensitive, chemotherapy has not been shown to prolong life in patients with anaplastic gliomas.
  • Despite promising preclinical and early clinical results, there is currently not enough level 1 evidence to justify concomitant and adjuvant temozolomide as standard therapy for patients with newly diagnosed anaplastic gliomas.
  • Further investigation is needed to better define the role of chemotherapy in patients with anaplastic gliomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Carcinoma / radiotherapy. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Clinical Trials as Topic. Combined Modality Therapy. DNA Modification Methylases. DNA Repair Enzymes. Humans. Oligodendroglioma / drug therapy. Oligodendroglioma / genetics. Oligodendroglioma / radiotherapy. Salvage Therapy. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17027279.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Number-of-references] 93
  •  go-up   go-down


18. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol; 2009 Dec 10;27(35):5874-80
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
  • PURPOSE: The standard of care for anaplastic gliomas is surgery followed by radiotherapy.
  • The NOA-04 phase III trial compared efficacy and safety of radiotherapy followed by chemotherapy at progression with the reverse sequence in patients with newly diagnosed anaplastic gliomas.
  • PATIENTS AND METHODS: Patients (N = 318) were randomly assigned 2:1:1 (A:B1:B2) to receive conventional radiotherapy (arm A); procarbazine, lomustine (CCNU), and vincristine (PCV; arm B1); or temozolomide (arm B2) at diagnosis.
  • Anaplastic oligodendrogliomas and oligoastrocytomas share the same, better prognosis than anaplastic astrocytomas.
  • CONCLUSION: Initial radiotherapy or chemotherapy achieved comparable results in patients with anaplastic gliomas.
  • IDH1 mutations are a novel positive prognostic factor in anaplastic gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy. Glioma / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Isocitrate Dehydrogenase / genetics. Kaplan-Meier Estimate. Lomustine / administration & dosage. Lomustine / adverse effects. Male. Middle Aged. Mutation. Procarbazine / administration & dosage. Procarbazine / adverse effects. Promoter Regions, Genetic. Proportional Hazards Models. Radiotherapy, Adjuvant / adverse effects. Risk Assessment. Risk Factors. Time Factors. Treatment Failure. Tumor Suppressor Proteins / genetics. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Dec 10;27(35):5861-2 [19901101.001]
  • [ErratumIn] J Clin Oncol. 2010 Feb 1;28(4):708
  • (PMID = 19901110.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; PCV protocol
  •  go-up   go-down


19. Deighton RF, McGregor R, Kemp J, McCulloch J, Whittle IR: Glioma pathophysiology: insights emerging from proteomics. Brain Pathol; 2010 Jul;20(4):691-703
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioma pathophysiology: insights emerging from proteomics.
  • Gliomas account for >50% of adult primary intracranial tumors, with malignant gliomas (anaplastic astrocytomas and glioblastoma multiforme) being the most common.
  • In glioma, the application of proteomic technology has identified altered protein expression but without consistency of these alterations or their biological significance being established.
  • A systematic review of multiple independent proteomic analyses of glioma has demonstrated alterations of 99 different proteins.
  • Importantly 10 of the 99 proteins found differentially expressed in glioma [PHB, Hsp20, serum albumin, epidermal growth factor receptor (EGFR), EA-15, RhoGDI, APOA1, GFAP, HSP70, PDIA3] were identified in multiple publications.
  • The protein network discovered (containing TP53 and RB1 at its core) compliments recent findings in genomic studies of malignant glioma.
  • The novel perspective provided by network analysis indicates that the potential of this technology to explore crucial aspects of glioma pathophysiology can now be realized but only if the conceptual and technical limitations highlighted in this review are addressed.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Proteomics


20. Salomão JF, Pone MV, da Silva AR, Leibinger RD, Bellas AR, Campos JM, Garrido JR, Vanazzi E, de Barros AC, Pone SM, Boechat MB: Positive reaction for cysticercosis and multicentric anaplastic oligoastrocytoma. Childs Nerv Syst; 2006 Feb;22(2):182-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive reaction for cysticercosis and multicentric anaplastic oligoastrocytoma.
  • INTRODUCTION: An unusual case of positive immunological testing for cysticercosis in the cystic fluid obtained from an anaplastic oligoastrocytoma is presented.
  • CASE REPORT: A 15-year-old boy was admitted with multiple brain lesions.
  • As the patient deteriorated the cystic lesion was removed and the diagnosis of anaplastic oligoastrocytoma was established.
  • A second lesion was eventually approached and the histopathological diagnosis of both specimens concurred.
  • DISCUSSION: Although some authors believe that chronic inflammatory changes following neurocysticercosis could induce the formation of brain tumors, this association may be a mere coincidence.
  • We believe that the similarity of the glioma and cysticercosis antigens may be the cause of the positive reactions in the cystic fluid.
  • [MeSH-major] Brain Neoplasms / complications. Cysticercosis / complications. Oligodendroglioma / complications

  • Genetic Alliance. consumer health - Cysticercosis.
  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15778869.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


21. Yamamoto Y, Nishiyama Y, Kimura N, Kameyama R, Kawai N, Hatakeyama T, Kaji M, Ohkawa M: 11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET. Mol Imaging Biol; 2008 Sep;10(5):281-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET.
  • PURPOSE: The aim of the study is to retrospectively investigate the usefulness of 11C-acetate (ACE)-positron emission tomography (PET) for evaluation of brain glioma, in comparison with 11C-methionine (MET) and 2-deoxy-2-18F-fluoro-D-glucose (FDG).
  • PROCEDURES: Fifteen patients with brain glioma referred to initial diagnosis were examined with ACE, MET, and FDG-PET.
  • Five patients had low-grade gliomas (grade II), three had anaplastic astrocytomas (grade III), and seven had glioblastomas (grade IV).
  • For semiquantitative analysis, the standardized uptake value (SUV) and tumor to contralateral normal gray matter (T/N) ratio were calculated.
  • CONCLUSIONS: ACE PET is a potentially useful radiotracer for detecting brain gliomas and differentiating high-grade gliomas.
  • [MeSH-major] Acetates. Brain Neoplasms / diagnosis. Fluorodeoxyglucose F18. Glioma / diagnosis. Methionine. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Mol Imaging Biol. 2009 Jul-Aug;11(4):223 [19326176.001]
  • (PMID = 18543041.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetates; 0 / Carbon Isotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AE28F7PNPL / Methionine
  •  go-up   go-down


22. Preusser M, Haberler C, Hainfellner JA: Malignant glioma: neuropathology and neurobiology. Wien Med Wochenschr; 2006 Jun;156(11-12):332-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant glioma: neuropathology and neurobiology.
  • Malignant gliomas may manifest at any age including congenital and childhood cases.
  • Malignant gliomas comprise a spectrum of different tumor subtypes.
  • Within this spectrum, glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma share as basic features preferential location in cerebral hemispheres, diffuse infiltration of brain tissue, fast tumor growth with fatal outcome within months or years.
  • Invasion of glioma cells requires interaction with the extracellular matrix and with surrounding cells of the healthy brain tissue.
  • Vascular proliferates and tissue necrosis are characteristic features of malignant gliomas, in particular glioblastoma.
  • These features are most likely the consequence of rapidly increasing tumor mass that is inadequately oxygenized by the preexisting vasculature.
  • In malignant glioma, distinct molecular pathways including the p53 pathway, the RB pathway and the EGFR pathway show frequent alterations that seem to be pathogenetically relevant.
  • Methylguanine-methyltransferase (MGMT) promoter methylation status in glioblastoma and 1p19q deletion status in anaplastic oligodendroglioma are associated with response to chemotherapy.
  • The role of neuropathology and neurobiology in neurooncology is 1. to provide a clinically meaningful classification of brain tumors on basis of pathobiological factors, 2. to clarify etiology and pathogenesis of brain tumors as rational basis for development of new diagnostic tests and therapies, and 3. to translate testing for new clinically relevant molecular parameters into clinical application.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology
  • [MeSH-minor] Adult. Brain / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Child. Chromosome Aberrations. Female. Humans. Infant. Male. Neoplasm Invasiveness / pathology. Prognosis


23. Amberger-Murphy V: Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets; 2009 May;9(3):381-90
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia helps glioma to fight therapy.
  • Despite major improvements in the surgical management the prognosis for patients bearing malignant gliomas is still dismal.
  • Malignant gliomas are notoriously resistant to treatment and the survival time of patients is between 3-8 years for low-grade and anaplastic gliomas and 6 - 12 month for glioblastoma.
  • Increasing malignancy of gliomas correlates with an increase in cellularity and a poorly organized tumor vasculature leading to insufficient blood supply, hypoxic areas and ultimately to the formation of necrosis, a characteristic of glioblastoma.
  • Hypoxia induces either directly or indirectly (through the activation of transcription factors) changes in the biology of a tumor and its microenvironment leading to increased aggressiveness and tumor resistance to chemotherapy and radiation.
  • This review is focused on hypoxia-induced molecular changes affecting glioma biology and therapy.
  • [MeSH-major] Brain Neoplasms / drug therapy. Glioma / drug therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19442057.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 11062-77-4 / Superoxides; 31C4KY9ESH / Nitric Oxide
  • [Number-of-references] 123
  •  go-up   go-down


24. Sugita Y, Ono T, Ohshima K, Niino D, Ito M, Toda K, Baba H: Brain surface spindle cell glioma in a patient with medically intractable partial epilepsy: a variant of monomorphous angiocentric glioma? Neuropathology; 2008 Oct;28(5):516-20
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain surface spindle cell glioma in a patient with medically intractable partial epilepsy: a variant of monomorphous angiocentric glioma?
  • We report a case of brain surface angiocentric glioma in a 6-year-old Japanese boy with medically intractable partial epilepsy.
  • At surgery, a yellowish tumor was localized in the superficial cortex.
  • Histologically, the tumor was predominantly composed of elongated astrocytic cells forming rings around blood vessels.
  • Tumor cells circumferential to vessels predominanted in low cellurarity areas, whereas radial alignment with perivascular pseudorosettes was observed in more cellular regions.
  • The tumor cells showed variable cytoplasmic immunoreactivity with GFAP.
  • These findings were more likely monomorphous angiocentric glioma, which was first described by Wang et al. in 2005.
  • However, in our case the tumor had a small foci of polymorphous appearance and a comparatively high MIB-1 labeling index (8%).
  • Therefore, the present case may be an atypical form of monomorphous angiocentric glioma.
  • However, no de novo anaplastic monomorphous angiocentric glioma similar to our case has yet been reported in the literature.
  • It remains to be determined whether the behavior of monomorphous angiocentric glioma is an example of benign biological characteristics or whether it more closely resembles a low-grade malignant tumor.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / pathology. Epilepsies, Partial / etiology. Glioma / complications. Glioma / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Malformations of Cortical Development / pathology. Neurosurgical Procedures

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179412.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


25. Parbel S, Vlaho S, Gebhardt B, Porto L, Hattingen E, Klingebiel T, Böhles H, Kieslich M: [Diagnostic difficulties in encephalitis and glioma]. Klin Padiatr; 2007 Jul-Aug;219(4):222-4
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic difficulties in encephalitis and glioma].
  • The differential diagnosis between cerebral glioma and infective lesions can be very difficult to distinguish by MRI only.
  • Brain biopsy revealed anaplastic astrocytoma (WHO III).
  • CONCLUSION: This case report shows that cerebral glioma can mimick infective brain disease and that MR-spectroscopy is an important non-invasive tool in this differential diagnosis.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Stem Neoplasms / diagnosis. Cerebellar Neoplasms / diagnosis. Encephalitis / diagnosis. Magnetic Resonance Spectroscopy. Pons
  • [MeSH-minor] Aspartic Acid / analogs & derivatives. Aspartic Acid / analysis. Child. Choline / analysis. Creatine / analysis. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Encephalitis.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865652.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


26. Goebell E, Paustenbach S, Vaeterlein O, Ding XQ, Heese O, Fiehler J, Kucinski T, Hagel C, Westphal M, Zeumer H: Low-grade and anaplastic gliomas: differences in architecture evaluated with diffusion-tensor MR imaging. Radiology; 2006 Apr;239(1):217-22
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade and anaplastic gliomas: differences in architecture evaluated with diffusion-tensor MR imaging.
  • PURPOSE: To prospectively evaluate whether diffusion-tensor magnetic resonance (MR) imaging depicts differences in World Health Organization (WHO) grade II and III glial brain tumors on the basis of tumor architecture and peritumoral tract invasion.
  • Diffusion-tensor MR imaging was performed in 23 patients (15 men, eight women; mean age, 47 years) with histologically confirmed brain gliomas.
  • Eleven of the 23 tumors were low-grade gliomas (WHO grade II) and 12 were anaplastic gliomas (WHO grade III).
  • Regions of interest were placed in the tumor center, tumor border, normal-appearing white matter (NAWM) adjacent to the tumor, and NAWM of the contralateral hemisphere. fractional anisotropy (FA) ratios were calculated for regions of interest in relation to the NAWM of the contralateral hemisphere.
  • RESULTS: Median FA ratios for grade II versus grade III gliomas were 0.406 versus 0.405, respectively, for tumor center, 0.733 versus 0.449, respectively, for tumor border, and 0.962 versus 0.943, respectively, for NAWM adjacent to the tumor.
  • Differences in FA ratio between low-grade and high-grade tumors were significant in the tumor border only (P = .01).
  • Differences in FA ratio were not significant between low-grade and high-grade gliomas in the tumor center or in the NAWM adjacent to the tumor.
  • Low FA ratios in the tumor center are consistent with a high degree of disorganization of myelinated fiber tracts in the center of both low-grade and high-grade gliomas.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging. Glioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484348.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Takaya S, Hashikawa K, Turkheimer FE, Mottram N, Deprez M, Ishizu K, Kawashima H, Akiyama H, Fukuyama H, Banati RB, Roncaroli F: The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas. J Neurooncol; 2007 Oct;85(1):95-103
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas.
  • This molecule is commonly up-regulated in inflammatory, degenerative, infective and ischaemic lesions of the central nervous system but it has never been reported in glioma-infiltrating microglia.
  • We examined two anaplastic astrocytomas showing minimal contrast-enhancement and therefore little damage of the blood brain barrier to minimise the presence of blood borne macrophages within tumour tissue.
  • Glioma-infiltrating microglia were characterised for molecules involved in antigen presentation and cytotoxic activity.
  • The expression profile of four anaplastic astrocytomas was also exploited and results were compared to the profile of eleven samples of normal temporal lobe and nine cases of PD.
  • Pathological investigation revealed that glioma-infiltrating microglia failed to express PBR and cytotoxic molecules although some cells still expressed antigen presenting molecules.
  • Our results demonstrated PBR suppression in glioma-infiltrating microglia and suggested that PBR may have a relevant role in modulating the anti-tumour inflammatory response in astrocytic tumours.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Microglia / metabolism. Microglia / pathology. Receptors, GABA-A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520179.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ MC/ U120085814
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Isoquinolines; 0 / RNA, Messenger; 0 / Radiopharmaceuticals; 0 / Receptors, GABA-A; YNF83VN1RL / PK 11195
  •  go-up   go-down


28. Koga T, Morita A, Maruyama K, Tanaka M, Ino Y, Shibahara J, Louis DN, Reifenberger G, Itami J, Hara R, Saito N, Todo T: Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation. Neuro Oncol; 2009 Aug;11(4):446-51
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation.
  • Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytic neoplasm of the brain.
  • Some PXAs are accompanied by anaplastic features and are difficult to manage because of frequent recurrences that lead to early death.
  • We report a case of PXA with anaplastic features treated with stereotactic irradiation (STI) that resulted in long-term control of repeatedly recurring nodules throughout the neuraxis.
  • A 47-year-old woman presented with an epileptic seizure due to a large tumor in the right frontal lobe.
  • The tumor was resected and diagnosed as PXA with anaplastic features.
  • Two years later, the patient developed a tumor nodule in the cervical spinal cord that histologically corresponded to a small-cell glioma with high cellularity and prominent MIB-1 (mindbomb homolog 1) labeling.
  • However, diffuse dissemination along the craniospinal axis eventually progressed, and she died 66 months after initial diagnosis.
  • STI may be an effective therapeutic tool for controlling nodular dissemination of PXA with anaplastic features.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 1999 Oct;13(5):516-9 [10627788.001]
  • [Cites] Histopathology. 2008 Jan;52(2):183-93 [18184267.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):563-6 [11585332.001]
  • [Cites] Ultrastruct Pathol. 2001 Nov-Dec;25(6):469-78 [11783911.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Dec;61(12):1092-9 [12484572.001]
  • [Cites] Childs Nerv Syst. 2004 Feb;20(2):119-22 [14669022.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] Neurosurgery. 1985 May;16(5):703-6 [4000446.001]
  • [Cites] Neurosurgery. 1988 Feb;22(2):422-7 [3352896.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):463-8 [2644402.001]
  • [Cites] Acta Neuropathol. 1989;78(6):585-93 [2816300.001]
  • [Cites] Clin Neuropathol. 1993 Mar-Apr;12(2):97-101 [8477554.001]
  • [Cites] Acta Neuropathol. 1994;87(3):225-32 [8009954.001]
  • [Cites] Neurosurg Rev. 1996;19(1):13-6 [8738360.001]
  • [Cites] Acta Neuropathol. 1996;91(3):293-7 [8834542.001]
  • [Cites] Childs Nerv Syst. 1997 Jan;13(1):50-6 [9083703.001]
  • [Cites] J Neurosurg Sci. 1998 Sep;42(3):153-7 [10192056.001]
  • [Cites] Cancer. 1999 May 1;85(9):2033-45 [10223246.001]
  • [Cites] Acta Neurochir (Wien). 2006 Jan;148(1):67-71; discussion 71 [15912255.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4):674-85; discussion 674-85 [16575331.001]
  • [Cites] Neurosurgery. 2006 Jun;58(6):1081-9; discussion 1081-9 [16723887.001]
  • [Cites] J Neurol Sci. 2007 Jan 31;252(2):144-53 [17189643.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):1088-97 [16909113.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):184-92 [11465399.001]
  • (PMID = 19164434.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2743225
  •  go-up   go-down


29. Hong X, Nelson KK, deCarvalho AC, Kalkanis SN: Heparanase expression of glioma in human and animal models. J Neurosurg; 2010 Aug;113(2):261-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparanase expression of glioma in human and animal models.
  • OBJECT: Mammalian heparanase has been shown to function in tumor progression, invasion, and angiogenesis.
  • To clarify its expression in gliomas, human glioma tissues and glioma animal models were investigated.
  • METHODS: The expression of heparanase mRNA was determined in 33 resected human glioma tissues by semiquantitative real-time polymerase chain reaction.
  • RESULTS: The authors found that heparanase mRNA is greatly increased in gliomas including oligodendroglioma (9 samples), anaplastic astrocytoma (11 samples), and GBM (13 samples) as compared with healthy brain mRNA (3 samples).
  • Note, however, that no significant difference was observed among the 3 tumor groups.
  • Increased heparanase expression was also found in tumor tissues on Western blotting.
  • Heparanase-expressing cells, including GBM tumor cells and neovessel endothelial cells, exhibited decreased expression of CD44, a cell adhesion molecule on the cell membrane that is important for regulating tumor invasion.
  • In addition, heparanase-expressing tumor cells showed an elevated density of the cell proliferation marker Ki 67, as compared with its density in non-heparanase-expressing tumor cells, suggesting that heparanase expression is correlated with enhanced tumor proliferation.
  • Two animal glioma models were tested for heparanase expression.
  • Both murine astrocytoma cells (Ast11.9-2) and cultured primary human GBM neurospheres expressed heparanase when grown in animal brain tissue.
  • CONCLUSIONS: Glioma tissues contain increased levels of heparanase.
  • Multiple cell types contribute to the expression of heparanase, including neovessel endothelial cells, tumor cells, and infiltrated neutrophils.
  • [MeSH-major] Brain Neoplasms / physiopathology. Glioblastoma / physiopathology. Glucuronidase / genetics. Glucuronidase / metabolism
  • [MeSH-minor] Animals. Antigens, CD44 / genetics. Antigens, CD44 / metabolism. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / physiopathology. Blotting, Western. Disease Models, Animal. Endothelial Cells / physiology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Mice. Mice, Inbred C57BL. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. Oligodendroglioma / physiopathology. RNA, Messenger / metabolism. Rats. Rats, Nude. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19835469.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44 protein, human; 0 / RNA, Messenger; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


30. Chamberlain MC, Glantz MJ: CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. J Neurooncol; 2008 Sep;89(2):231-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
  • OBJECTIVE: A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS).
  • Time to tumor progression ranged from 2 to 13.5 months (median: 4.5 months).
  • CONCLUSIONS: CPT-11 demonstrated modest efficacy (similar to other salvage glioma regimens) with acceptable toxicity in this cohort of adults with recurrent, 1p19q co-deleted AO all of whom had failed prior TMZ chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Oligodendroglioma / drug therapy

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480965.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


31. Nagy M, Schulz-Ertner D, Bischof M, Welzel T, Hof H, Debus J, Combs SE: Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas. Tumori; 2009 May-Jun;95(3):317-24
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas.
  • PURPOSE: Patients with anaplastic gliomas have a more favorable overall survival than patients with glioblastomas.
  • After the primary diagnosis, a biopsy had been performed in 72 patients; subtotal and total resections were performed in 37 and 18 patients, respectively.
  • Median overall survival was 7 months for patients with anaplastic astrocytomas, 44 months for patients with mixed tumors, and 47 months for those with pure oligodendrogliomas.
  • CONCLUSION: Patients with WHO grade III anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas show favorable overall survival after postoperative radiotherapy compared with glioblastoma patients and should therefore be analyzed separately.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Glioma / pathology. Glioma / radiotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688970.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


32. Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T: Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci; 2009 Oct;100(10):1996-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.
  • In the present study, R172 mutation of the IDH2 gene was detected in one anaplastic astrocytoma.
  • IDH1 or IDH2 mutations were frequently in oligodendrogliomas (67%), anaplastic astrocytomas (62%), anaplastic oligoastrocytomas (75%), anaplastic oligodendrogliomas (50%), secondary glioblastomas (67%), gangliogliomas (38%), and anaplastic gangliogliomas (60%).
  • Mutations of the IDH1 or IDH2 genes were significantly associated with improved outcome in patients with anaplastic astrocytomas.
  • Our data suggest that IDH1 or IDH2 mutation plays a role in early tumor progression of several types of glioma and might arise from a common glial precursor.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Glioma / genetics. Isocitrate Dehydrogenase / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19765000.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


33. Kocher M, Kunze S, Eich HT, Semrau R, Müller RP: Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol; 2005 Mar;181(3):157-63
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
  • PURPOSE: To evaluate the feasibility, safety and efficacy of daily temozolomide concurrent with postoperative radiotherapy in malignant glioma.
  • PATIENTS AND METHODS: From 11/1999 to 03/2003, n = 81 patients aged 15-72 years (median 52 years, Karnofsky score 80-100% in 83%) suffering from primary glioblastoma (n = 47), anaplastic astrocytoma (n = 6), anaplastic oligodendroglioma (n = 16), and recurrent glioma (n = 12) were treated.
  • CONCLUSION: Postoperative radiochemotherapy with 30-33 daily doses of temozolomide (75 mg/m(2)) is safe in patients with malignant glioma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / surgery. Dacarbazine / analogs & derivatives. Glioma / surgery

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756519.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


34. Dreyfuss JM, Johnson MD, Park PJ: Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer; 2009 Sep 04;8:71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers.
  • BACKGROUND: Anaplastic astrocytoma (AA) and its more aggressive counterpart, glioblastoma multiforme (GBM), are the most common intrinsic brain tumors in adults and are almost universally fatal.
  • A deeper understanding of the molecular relationship of these tumor types is necessary to derive insights into the diagnosis, prognosis, and treatment of gliomas.
  • Although genomewide profiling of expression levels with microarrays can be used to identify differentially expressed genes between these tumor types, comparative studies so far have resulted in gene lists that show little overlap.
  • CONCLUSION: We have performed a meta-analysis of genome-scale mRNA expression data for 289 human malignant gliomas and have identified a list of >900 probe sets and >20 pathways that are significantly different between GBM and AA.
  • These feature lists could be utilized to aid in diagnosis, prognosis, and grade reduction of high-grade gliomas and to identify genes that were not previously suspected of playing an important role in glioma biology.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1371-7 [10604735.001]
  • [Cites] Mol Endocrinol. 2000 Jun;14(6):848-62 [10847587.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20315-23 [10783396.001]
  • [Cites] BMC Bioinformatics. 2008;9:63 [18226260.001]
  • [Cites] Genomics. 2008 May;91(5):395-406 [18343632.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1013-24 [18445660.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 5;373(4):539-44 [18590702.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] BMC Bioinformatics. 2009;10:1 [19118496.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] FASEB J. 2001 Feb;15(2):458-66 [11156961.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1279-92 [11943713.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4427-33 [12154050.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1695-700 [12414516.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6205-10 [12414648.001]
  • [Cites] Acta Neuropathol. 2003 Jan;105(1):49-57 [12471461.001]
  • [Cites] Pancreas. 2003 Jan;26(1):56-64 [12499918.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1138-43 [12615733.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2361-73 [12700671.001]
  • [Cites] Genome Biol. 2003;4(4):210 [12702200.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):267-73 [12808457.001]
  • [Cites] Bioinformatics. 2003;19 Suppl 1:i84-90 [12855442.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):402-6; discussion 406 [14572960.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):212-21 [14734472.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):307-15 [14960456.001]
  • [Cites] Nat Biotechnol. 2004 May;22(5):615-21 [15122300.001]
  • [Cites] FEBS Lett. 2004 Aug 27;573(1-3):83-92 [15327980.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):32529-37 [8955077.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):895-900 [10029081.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3915-8 [10463582.001]
  • [Cites] BMC Bioinformatics. 2004 Oct 25;5:159 [15504239.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3166-78 [15231529.001]
  • [Cites] Genome Biol. 2005;6(2):R16 [15693945.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]
  • [Cites] Nat Methods. 2005 May;2(5):345-50 [15846361.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13544-9 [16174746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] J Bioinform Comput Biol. 2005 Oct;3(5):1171-89 [16278953.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):55-65 [16369572.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):233-47 [16612574.001]
  • [Cites] Biom J. 2006 Jun;48(3):435-50 [16845907.001]
  • [Cites] BMC Bioinformatics. 2006;7:359 [16872483.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5 [17099226.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11736-41 [17606927.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10296-303 [17974971.001]
  • [Cites] Neurosurg Rev. 2008 Jan;31(1):83-9; discussion 89-90 [17917751.001]
  • [Cites] Comput Biol Chem. 2008 Feb;32(1):38-46 [17988949.001]
  • [Cites] Bioinformatics. 2008 Feb 1;24(3):374-82 [18204063.001]
  • [Cites] Ann Vasc Surg. 2008 Mar;22(2):273-84 [18346582.001]
  • (PMID = 19732454.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM082798; United States / NIH HHS / OD / DP2 OD002319; United States / NIH HHS / OD / DP2OD002319; United States / NLM NIH HHS / LM / U54 LM008748; United States / NLM NIH HHS / LM / U54LM008748
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2743637
  •  go-up   go-down


35. Taal W, van der Rijt CD, Sillevis Smitt PA, Kros JM, van Heuvel I, Enting RH, van den Bent MJ: [Favourable result for temozolomide in recurrent high-grade glioma]. Ned Tijdschr Geneeskd; 2005 Jun 18;149(25):1393-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Favourable result for temozolomide in recurrent high-grade glioma].
  • OBJECTIVE: To describe the results of the treatment of recurrent glioma with temozolomide.
  • METHOD: This study evaluated 77 patients with a recurrent high-grade glioma who from August 1997-December 2003 were treated with temozolomide (150-200 mg/m2/day for 5 days per 28-day cycle) following surgery and radiotherapy at the Daniel den Hoed Oncology Centre of the Erasmus MC, Rotterdam, the Netherlands.
  • RESULTS: 15 patients received temozolomide for a recurrent anaplastic oligodendroglioma or mixed oligo-astrocytoma.
  • 35 patients underwent second-line chemotherapy with temozolomide after earlier chemotherapy with procarbazine, lomustine and vincristine for recurrent anaplastic oligodendroglioma or mixed oligo-astrocytoma.
  • 14 patients were treated with temozolomide for a recurrent anaplastic astrocytoma with a response of 35% and after 12 months in 8% of these patients there was no disease progression.
  • CONCLUSION. Temozolomide has an acceptable safety profile and may be regarded as the preferred treatment for recurrent anaplastic gliomas after radiotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1376-8 [15997689.001]
  • (PMID = 15997692.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


36. Yi L, Zhou ZH, Ping YF, Chen JH, Yao XH, Feng H, Lu JY, Wang JM, Bian XW: Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma. Mod Pathol; 2007 Oct;20(10):1061-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma.
  • A small population of stem cell-like precursors in solid tumors are linked to histological composition, progression, angiogenesis, metastasis, recurrence and drug resistance of a variety of malignant tumors.
  • Oligoastrocytoma is the most common brain mixed glioma composed of mixed cells of oligodendroglial and astrocytic phenotypes.
  • Identification and characterization of stem cell-like precursors in oligoastrocytoma may shed light on the oncogenesis of this unique type of tumor and assist in the design of novel therapeutic strategy.
  • Here, tumor stem cell-like precursors were identified from primary human anaplastic oligoastrocytomas by labeling of the tumor sections with nestin and CD133.
  • Tumor cells were cultured in vitro in stem cell medium with growth factors and the capacity of the surviving stem cell-like precursors to form tumor spheres was tested.
  • The tumor spheres were further injected subcutaneously into nude mice to observe the contribution of stem cell-like precursors to histological composition and tumor progression.
  • These cells differentiated into tumor cells with both oligodendroglial and astrocytic characteristics and formed tumor spheres in vitro, which upon implantation in nude mice, grew into tumor nodules containing nestin+/CD133+ cells at levels higher than in the primary tumor tissues.
  • This study revealed for the first time that anaplastic human oligoastrocytomas contained stem cell-like precursors, which exhibit neural stem cell properties with tumorigenicity.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Animals. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Brain / pathology. Fluorescent Antibody Technique, Indirect. Glycoproteins / analysis. Humans. Intermediate Filament Proteins / analysis. Magnetic Resonance Imaging. Mice. Mice, Nude. Neoplasm Transplantation. Nerve Tissue Proteins / analysis. Nestin. Peptides / analysis. Spheroids, Cellular / chemistry. Spheroids, Cellular / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660801.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Peptides
  •  go-up   go-down


37. Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H: EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia; 2005 Aug;7(8):717-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.
  • We demonstrate in the current study that the EphA2 protein is restrictedly expressed in primary glioblastoma multiforme and anaplastic astrocytoma tissues in comparison to normal brain tissues.
  • To evaluate the possibility of targeting EphA2 in glioma vaccine strategies, we stimulated human leukocyte antigen (HLA) A2+ peripheral blood mononuclear cells (PBMCs) obtained from healthy donors and glioma patients with autologous dendritic cells (DCs) loaded with synthetic EphA2883-891 peptide (TLADFDPRV), which has previously been reported to induce interferon-gamma in HLA-A2+ PBMCs.
  • Stimulated PBMCs demonstrated antigen-specific cytotoxic T lymphocyte (CTL) responses as detected by specific lysis of T2 cells loaded with the EphA2883 peptide as well as HLA-A2+ glioma cells, SNB19 and U251, that express EphA2.
  • Taken together, these data suggest that EphA2883-891 may be an attractive antigen epitope for molecularly targeted glioma vaccines.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Gene Ther. 2001 Mar 20;12(5):575-95 [11268289.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):13-20 [12952282.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2851-5 [12231526.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7011-26 [12370823.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):59-68 [12650608.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4481-9 [12907621.001]
  • [Cites] Oncogene. 2000 Dec 7;19(52):6043-52 [11146556.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8476-80 [14679012.001]
  • [Cites] J Clin Invest. 2004 Feb;113(3):425-33 [14755339.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):218-27 [15102348.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] J Neurosurg. 1981 Jul;55(1):32-42 [6165811.001]
  • [Cites] J Exp Med. 1997 Jun 16;185(12):2043-51 [9182675.001]
  • [Cites] Surgery. 1999 Aug;126(2):112-20 [10455872.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):226-31 [15671550.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2301-6 [11280802.001]
  • (PMID = 16207473.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS040923; United States / NINDS NIH HHS / NS / P01 NS40923
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A2 Antigen; EC 2.7.10.1 / Receptor, EphA2
  • [Other-IDs] NLM/ PMC1501889
  •  go-up   go-down


38. Broniscer A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, Bowers DC, Iacono LC, Merchant TE, Stewart CF, Houghton PJ, Kun LE, Ledet D, Gajjar A: Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol; 2006 Feb;76(3):313-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
  • Chemotherapy is commonly used in the treatment of children with high-grade glioma, although its usefulness is uncertain.
  • We conducted a multi-institutional study to evaluate the efficacy of temozolomide given after radiotherapy in children with newly diagnosed high-grade glioma and unfavorable low-grade glioma (gliomatosis cerebri or bithalamic involvement).
  • Tumors most commonly involved cerebral hemispheres (n = 13, 42%) and thalamus (n = 14, 45%).
  • The predominant histologic diagnoses were glioblastoma multiforme (n = 15, 48%) and anaplastic astrocytoma (n = 10, 32%).
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200343.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA21765
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


39. Woodworth G, McGirt MJ, Samdani A, Garonzik I, Olivi A, Weingart JD: Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen. Neurol Res; 2005 Jun;27(4):358-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen.
  • OBJECTIVES: Tissue heterogeneity and rapid tumor progression may decrease the accuracy a prognostic value of stereotactic brain biopsy in the diagnosis of gliomas.
  • Correct tumor grading is therefore dependent on the accuracy of biopsy needle placement.
  • There has been a dramatic increase in the utilization of frameless image-guided stereotactic brain biopsy; however, its accuracy in the diagnosis of glioma remains unstudied.
  • METHODS: The diagnoses of 21 astrocytic brain tumors were derived using image-guided stereotactic biopsy (12 frame-based, nine frameless) and followed by open resection of the lesion 1.5 (0.5-4) months later.
  • The histologic diagnoses yielded by the biopsy were compared with subsequent histologic diagnosis from open tumor resection.
  • In three (14%) cases, biopsy specimens were adequate to diagnose glioma; however, histology was insufficient for definitive tumor grading.
  • Anaplastic oligodendroglioma (ODG) was under-graded as low-grade ODG in one (5%) case.
  • DISCUSSION: Both frameless and frame-based MRI-guided stereotactic brain biopsy are safe and accurately represent the larger glioma mass sufficiently to guide subsequent therapy.
  • Large tumor volume had a higher incidence of non-concordance.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Magnetic Resonance Imaging. Stereotaxic Techniques

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949232.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Naydenov E, Tzekov C, Minkin K, Nachev S, Marinov M: [Malignant progression of an anaplastic ganglioglioma into a glioblastoma multiforme--report on two cases and review of the literature]. Khirurgiia (Sofiia); 2009;(2-3):69-74
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant progression of an anaplastic ganglioglioma into a glioblastoma multiforme--report on two cases and review of the literature].
  • INTRODUCTION: Ganglioglioma is an uncommon type of primary brain tumors.
  • In most of the cases the tumor demonstrates benign clinical behaviour with long-term patients' survival.
  • We present two cases ofhistologically confirmed anaplastic ganglioglioma in which malignant progression into a glioblastoma multiforme was seen.
  • The tumor was excised partially and the histological result was anaplastic ganglioglioma (World Health Organization - WHO. gr. III).
  • A local tumor recurrence was found and the patient underwent second operative intervention with gross total tumor resection.
  • IV glioma). The patient improved after the procedure.
  • An involvement of the contralateral cerebral hemisphere was found on control CT-scan ten months later.
  • The patient died after one month, 23 months after her initial diagnosis.
  • MRI data for large, heterointense tumor lesion in the left frontal lobe was found.
  • A subtotal tumor removal was made.
  • The histological result was anaplastic ganglioglioma (WHO gr. ILL).
  • Data for additional local tumor growth was found on control CT-scan one month later.
  • 20 months after the initial diagnosis.
  • The tumor behaviour may vary between the patients in spite of the similar histological characteristics which indicates the possible presence of different tumor subtypes.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology


41. Uzuka T, Kakita A, Inenaga C, Takahashi H, Tanaka R, Takahashi H: Frontal anaplastic oligodendroglioma showing multi-organ metastases after a long clinical course. Case report. Neurol Med Chir (Tokyo); 2007 Apr;47(4):174-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontal anaplastic oligodendroglioma showing multi-organ metastases after a long clinical course. Case report.
  • A 17-year-old woman presented with an anaplastic oligodendroglioma manifesting as generalized seizure.
  • Neuroimaging studies revealed a right frontal tumor.
  • Histological examinations of biopsy specimens revealed that the tumor was oligodendroglial in nature.
  • Total resection was repeated four times, and malignant change was evident within the tissues.
  • The final diagnosis was anaplastic oligodendroglioma.
  • Despite irradiation, combination chemotherapy, and interstitial hyperthermia, the tumor grew rapidly but was confined to the cavity created by previous removal operations.
  • At autopsy, generalized metastases from the tumor were identified at various sites, including the dura mater covering the frontal lobes and thoracic cord, cavernous sinus, tuberculum sellae, spleen, liver, pancreas, lungs, paratracheal lymph nodes, vertebral bodies, ribs, sternum, pelvis, dorsal root ganglia, and iliopsoas muscle.
  • This rare case of cerebral anaplastic oligodendroglioma developed in adolescence, and rapid hematogenous spread of the glioma cells into the systemic organs occurred after a relatively long clinical course.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe. Oligodendroglioma / secondary

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17457022.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Hlaihel C, Guilloton L, Guyotat J, Streichenberger N, Honnorat J, Cotton F: Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. J Neurooncol; 2010 Mar;97(1):73-80
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas.
  • The aim of our study was to evaluate the role of proton magnetic resonance (MR) spectroscopy and MR perfusion in the follow-up of low-grade gliomas, since conventional MR imaging (MRI) is not reliable in detecting the passage from a low- to high-grade tumor.
  • Twenty-one patients with a World Health Organisation (WHO) grade II glioma were followed up using proton MR spectroscopy, perfusion, and conventional MRIs.
  • Five out of the 21 patients had an anaplastic transformation.
  • A choline to creatine ratio (choline/creatine ratio) above 2.4 is associated with an 83% risk of a malignant transformation in an average delay of 15.4 months.
  • The choline/creatine ratio at this threshold was more efficient than perfusion MR in detecting the anaplastic transformation, with sensitivity of 80% and specificity of 94%.
  • An increased choline/creatine ratio seemed to occur an average 15 months before the elevation of relative cerebral blood volume (rCBV).
  • The mean annual growth of low-grade glioma was 3.65 mm.
  • A growth rate higher than 3 mm per year was also correlated with greater risk of anaplastic transformation.
  • Proton magnetic resonance spectroscopy should be recommended in the follow-up of low-grade gliomas since the choline/creatine ratio can predict anaplastic transformation before perfusion abnormalities, with high positive predictive value of 83%.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727562.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Protons; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


43. Massimino M, Biassoni V: Use of high-dose chemotherapy in front-line therapy of childhood malignant glioma. Expert Rev Anticancer Ther; 2006 May;6(5):709-17
Genetic Alliance. consumer health - Glioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of high-dose chemotherapy in front-line therapy of childhood malignant glioma.
  • Brain tumors are the second most common cancer in pediatric patients and the main cause from death of malignant tumors in this age group.
  • High-grade or malignant glioma, among which anaplastic astrocytomas and glioblastoma are the most prevalent histotypes, represent 10% of pediatric brain tumors and, taken as a whole, are the second most frequent malignant histotype after medulloblastoma.
  • Different trials have explored the role of high-dose chemotherapy that, theoretically, could give an advantage to these patients by overcoming the blood-brain barrier, cell chemoresistance and inducing a wider number of responses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16759162.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 72
  •  go-up   go-down


44. Chansriwong P, Sirisinha T: Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital. J Med Assoc Thai; 2010 Feb;93 Suppl 2:S68-73
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
  • OBJECTIVE: To identify prognostic factors for survival and evaluate the effect of treatment on survival of patients with high-grade glioma treated at Ramathibodi Hospital.
  • MATERIAL AND METHOD: Medical records of patients with diagnosis of high-grade glioma registered in Ramathibodi cancer registry were reviewed.
  • Mean age of diagnosis was 41.86 years (range 18-71 years).
  • Histological findings were anaplastic glioma (22.20%), glioblastoma multiforme (63.90%) and mixed glioma (13.90%).
  • Of fifteen patients underwent total tumor removal, 17 patients had partial resection and in 4 cases biopsy alone was done.
  • In univariated analysis, the following favorable prognostic factors were identified: histological findings of glioblastoma multiforme (GBM) and mixed glioma, received radiotherapy.
  • CONCLUSION: Adult high-grade glioma had poor prognosis despite aggressive treatment.
  • Radiotherapy significantly improved survival while surgical tumor removal and chemotherapy did not.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / therapy. Carmustine / therapeutic use. Dacarbazine / analogs & derivatives. Glioma / therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21299082.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; U68WG3173Y / Carmustine
  •  go-up   go-down


45. Uzuka T, Takahashi H, Tanaka R: Interstitial hyperthermia with intra-arterial injection of adriamycin for malignant glioma. Neurol Med Chir (Tokyo); 2006 Jan;46(1):19-23; discussion 23
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial hyperthermia with intra-arterial injection of adriamycin for malignant glioma.
  • A new method for treating malignant glioma by concurrent intra-arterial injection of adriamycin during thermotherapy was performed in seven patients with malignant glioma, four males and three females, with five cases of glioblastoma and two of anaplastic oligodendroglioma.
  • Intra-arterial injection chemotherapy during hyperthermia is a promising therapeutic method for treatment of malignant glioma with few adverse effects.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Brain Neoplasms / therapy. Doxorubicin / administration & dosage. Glioma / therapy. Hyperthermia, Induced / methods

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Malignant hyperthermia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434821.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


46. Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM: A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol; 2009 Jan;91(2):183-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
  • This phase II study was designed to determine the objective response rate and 6-month progression free survival of adult patients with recurrent supratentorial anaplastic glioma when treated with the immune modulator, polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC).
  • Treatment with poly-ICLC continued until tumor progression.
  • Based on this study, poly-ICLC does not improve 6moPFS in patients with recurrent anaplastic gliomas but may be worth further study in combination with agents such as temozolomide.

  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):72-80 [17478095.001]
  • [Cites] J Transl Med. 2007;5:10 [17295916.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Apr 29;60(7):805-12 [18262679.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Immunology. 2008 Aug;124(4):480-8 [18248388.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Interferon Res. 1982;2(1):1-4 [6180095.001]
  • [Cites] Tex Rep Biol Med. 1981-1982;41:653-62 [6189230.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1058-65 [3155990.001]
  • [Cites] J Immunol. 1985 Oct;135(4):2483-91 [2411797.001]
  • [Cites] J Biol Response Mod. 1985 Oct;4(5):475-80 [2416882.001]
  • [Cites] J Biol Response Mod. 1985 Dec;4(6):640-9 [2418162.001]
  • [Cites] J Biol Response Mod. 1985 Dec;4(6):664-8 [2418164.001]
  • [Cites] Gynecol Oncol. 1986 Jul;24(3):359-61 [3721308.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1341-2 [3768878.001]
  • [Cites] J Urol. 1987 Feb;137(2):202-6 [3806804.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3005-10 [1591717.001]
  • [Cites] J Neurosurg. 1992 Jul;77(1):120-6 [1318961.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):75-83 [7721642.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1096-103; discussion 1103-4 [8727138.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Methods Mol Biol. 2007;383:277-301 [18217692.001]
  • (PMID = 18850068.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA062421-08; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / U01 CA062421-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Inducers; 24939-03-5 / Poly I-C; 25104-18-1 / Polylysine; 59789-29-6 / poly ICLC; 9004-32-4 / Carboxymethylcellulose Sodium
  • [Other-IDs] NLM/ NIHMS291833; NLM/ PMC3104130
  •  go-up   go-down


47. de Groot JF, Piao Y, Lu L, Fuller GN, Yung WK: Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol; 2008 Jun;88(2):121-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation.
  • High-grade gliomas release excitotoxic concentrations of glutamate which contributes to their malignant phenotype.
  • To improve our understanding of the mechanisms by which glutamate enhances tumor growth and invasion, we examined alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-mediated signaling in glioma cell lines. shRNA was used to stably knockdown GluR1, the most abundant AMPA receptor subunit in glioma, to evaluate its role in tumor signaling, proliferation and tumorigenicity.
  • In a tissue array, there was a statistically significant increase in GluR1 expression in glioblastoma samples compared to anaplastic astrocytoma and low-grade tumors.
  • Retroviral delivery of GluR1 shRNA in U251 and U87 glioma cells reduced GluR1 protein expression, inhibited AMPA-mediated increases in MAPK phosphorylation, and decreased glioma proliferation in vitro.
  • These results suggest that AMPA receptors are abundantly expressed in high-grade gliomas and gene silencing of the GluR1 AMPA receptor subunit results in abrogation of AMPA-mediated signaling and tumor growth.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation / drug effects. Glioma / prevention & control. RNA Interference / physiology. RNA, Small Interfering / therapeutic use. Receptors, AMPA / metabolism
  • [MeSH-minor] Animals. Carcinogenicity Tests. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Down-Regulation / drug effects. Down-Regulation / genetics. Humans. Ki-67 Antigen / metabolism. Mice. Mice, Nude. Microarray Analysis / methods. RNA, Double-Stranded / pharmacology. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317690.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / RNA, Double-Stranded; 0 / RNA, Small Interfering; 0 / Receptors, AMPA; 0 / glutamate receptor ionotropic, AMPA 1
  •  go-up   go-down


48. Alexiou GA, Tsiouris S, Vartholomatos G, Fotakopoulos G, Papadopoulos A, Kyritsis AP, Voulgaris S, Fotopoulos AD: Correlation of glioma proliferation assessed by flow cytometry with (99m)Tc-Tetrofosmin SPECT uptake. Clin Neurol Neurosurg; 2009 Dec;111(10):808-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of glioma proliferation assessed by flow cytometry with (99m)Tc-Tetrofosmin SPECT uptake.
  • OBJECTIVES: Brain single-photon emission computed tomography (SPECT) has been proposed as a potentially useful modality for the metabolic assessment of various brain tumors.
  • MATERIAL AND METHODS: In a 10-patient prospective pilot study we evaluated whether (99m)Tc-Tetrofosmin ((99m)Tc-TF) uptake correlates with glioma proliferative activity assessed by flow cytometric analysis. (99m)Tc-TF brain SPECT was performed shortly before surgical tumor excision.
  • RESULTS: Eight patients were diagnosed with glioblastoma multiform and 2 with anaplastic astrocytoma.
  • We found a significant positive linear correlation between (99m)Tc-TF uptake and percentage of tumor cells on the S-phase of the cell cycle (r=0.92, P=0.001).
  • CONCLUSION: Initial evidence suggests that (99m)Tc-TF could provide a non-invasive indicator of glioma proliferative activity.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radionuclide imaging. Glioma / pathology. Glioma / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19726126.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane; 9007-49-2 / DNA
  •  go-up   go-down


49. Oshiro S, Tsugu H, Komatsu F, Ohmura T, Ohta M, Sakamoto S, Fukushima T, Inoue T: Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res; 2009 Mar;29(3):911-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of temozolomide treatment in patients with high-grade glioma.
  • BACKGROUND: Numerous studies have reported the clinical efficacy of temozolomide (TMZ) treatment for high-grade glioma, but information on Japanese populations has been limited.
  • PATIENTS AND METHODS: The subjects comprised ten patients with high-grade glioma [glioblastoma multiforme (GBM), n=3, gliosarcoma (GS), n=1, anaplastic oligodendroglioma (AO), n=3, anaplastic mixed oligoastrocytoma (AOA), n=1, and anaplastic ependymoma (AE), n=2].
  • As second- or third-line chemotherapy, patients received TMZ for recurrence or tumor progression.
  • As combination therapy, the local administration of tumor necrosis factor-alpha and the addition of carboplatin and etoposide were included for three patients during the course of oral TMZ treatment.
  • One of the patients receiving combination therapy has continued to show shrinkage of the relapsed tumor.
  • CONCLUSION: TMZ chemotherapy is effective for the treatment of high-grade glioma in some patients without serious toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Treatment Outcome. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414327.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


50. Fuller GN, Mircean C, Tabus I, Taylor E, Sawaya R, Bruner JM, Shmulevich I, Zhang W: Molecular voting for glioma classification reflecting heterogeneity in the continuum of cancer progression. Oncol Rep; 2005 Sep;14(3):651-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular voting for glioma classification reflecting heterogeneity in the continuum of cancer progression.
  • Gliomas, the most common brain tumors, are generally categorized into two lineages (astrocytic and oligodendrocytic) and further classified as low-grade (astrocytoma and oligodendroglioma), mid-grade (anaplastic astrocytoma and anaplastic oligodendroglioma), and high-grade (glioblastoma multiforme) based on morphological features.
  • A strict classification scheme has limitations because a specific glioma can be at any stage of the continuum of cancer progression and may contain mixed features.
  • In this study, we used microarray technology to profile the gene expression of 49 human brain tumors and applied the k-nearest neighbor algorithm for classification.
  • We first trained the classification gene set with 19 of the most typical glioma cases and selected a set of genes that provide the lowest cross-validation classification error with k=5.
  • Thus, the actual voting results, which are typically used only to decide the winning class label in k-nearest neighbor algorithms, provide a useful method for gaining deeper insight into the stage of a tumor in the continuum of cancer development.
  • [MeSH-major] Brain Neoplasms / classification. Gene Expression Profiling. Glioma / classification. Oligonucleotide Array Sequence Analysis / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16077969.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  •  go-up   go-down


51. Tanriover N, Ulu MO, Sar M, Uzan M: Anaplastic oligoastrocytoma: previous treatment as a possible cause in a child with acute lymphoblastic leukemia. Childs Nerv Syst; 2007 Apr;23(4):469-73
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligoastrocytoma: previous treatment as a possible cause in a child with acute lymphoblastic leukemia.
  • INTRODUCTION: The authors present a 14-year-old patient who developed an anaplastic oligoastrocytoma of the left parietal lobe 9 years after a successful treatment of acute lymphoblastic leukemia (ALL).
  • He had a history of induction chemotherapy, intrathecal methotrexate and prophylactic whole brain irradiation (1,800 cGy in 10 fractions over 2 weeks).
  • DISCUSSION: Radiation-induced neoplasia is suggested to be the late complication of ALL treatment, and evaluation of large clinical series revealed a relationship between young age at ALL diagnosis (<6 years) and increased high-grade glioma occurrence risk.
  • CONCLUSION: The authors have reviewed previously reported cases of secondary central nervous system malignancies focusing on age at ALL diagnosis, and they think that synergistic action of therapeutic modalities could have played a role in the oncogenetic process.
  • [MeSH-major] Brain Neoplasms / etiology. Oligodendroglioma / etiology. Radiotherapy / adverse effects


52. Duffau H: Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity. Lancet Neurol; 2005 Aug;4(8):476-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity.
  • First, I review the natural history of LGG-growth, invasion, and anaplastic transformation.
  • Second, I discuss the contribution of new techniques, such as functional mapping, to our understanding of brain reorganisation in response to progressive growth of LGG.
  • Third, I consider the clinical implications of interactions between tumour progression and brain plasticity.
  • [MeSH-major] Brain / physiology. Brain Mapping. Brain Neoplasms / surgery. Glioma / surgery. Monitoring, Intraoperative. Neuronal Plasticity

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033690.001).
  • [ISSN] 1474-4422
  • [Journal-full-title] The Lancet. Neurology
  • [ISO-abbreviation] Lancet Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 150
  •  go-up   go-down


53. Widhalm G, Wolfsberger S, Minchev G, Woehrer A, Krssak M, Czech T, Prayer D, Asenbaum S, Hainfellner JA, Knosp E: 5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer; 2010 Mar 15;116(6):1545-52
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement.
  • 5-Aminolevulinic acid (5-ALA) leads to accumulation of fluorescent porphyrins in malignant glioma tissue, and is currently used for resection of malignant gliomas.
  • The aim of this study was to clarify whether 5-ALA might serve as marker for visualization of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement for precise intraoperative tissue sampling.
  • During glioma resection, positive fluorescence was noted by a modified neurosurgical microscope.
  • Histopathological diagnosis was established according to World Health Organization (WHO) 2007 criteria.
  • MIB-1 LI was significantly higher in 5-ALA-positive than in nonfluorescent areas within a given tumor.
  • CONCLUSIONS: The data indicate that 5-ALA is a promising marker for intraoperative visualization of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement.
  • Unaffected by intraoperative brain shift, 5-ALA may increase the precision of tissue sampling during tumor resection for histopathological grading, and therefore optimize allocation of patients to adjuvant treatments.
  • [MeSH-major] Aminolevulinic Acid. Brain Neoplasms / radionuclide imaging. Glioma / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Female. Humans. Intraoperative Period. Male. Middle Aged. Photosensitizing Agents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20108311.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


54. Chan DT, Poon WS, Chan YL, Ng HK: Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. Hong Kong Med J; 2005 Dec;11(6):452-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
  • OBJECTIVE: To determine the anti-tumour efficacy and safety profile of temozolomide in local Chinese patients with recurrent malignant glioma.
  • Histology reviewed by a neuropathologist was required to show anaplastic glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, or mixed anaplastic oligoastrocytoma) or glioblastoma multiforme.
  • RESULTS: Twenty-two patients with recurrent malignant glioma were recruited between January 2001 and July 2004.
  • CONCLUSION. Preliminary results showed that temozolomide had an acceptable safety profile and anti-tumour activity in recurrent malignant glioma in local Chinese population.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340021.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


55. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol; 2010 Dec;120(6):707-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
  • WHO grading of human brain tumors extends beyond a strictly histological grading system by providing a basis predictive for the clinical behavior of the respective neoplasm.
  • For example, patients with glioblastoma WHO grade IV usually show a less favorable clinical course and receive more aggressive first-line treatment than patients with anaplastic astrocytoma WHO grade III.
  • We sequenced the isocitrate dehydrogenase 1 gene (IDH1) at codon 132 in 382 patients with anaplastic astrocytoma and glioblastoma from the NOA-04 trial and from a prospective translational cohort study of the German Glioma Network.
  • Patients with anaplastic astrocytomas carried IDH1 mutations in 60%, and patients with glioblastomas in 7.2%.
  • IDH1 was the most prominent single prognostic factor (RR 2.7; 95% CI 1.6-4.5) followed by age, diagnosis and MGMT.
  • The sequence from more favorable to poorer outcome was (1) anaplastic astrocytoma with IDH1 mutation, (2) glioblastoma with IDH1 mutation, (3) anaplastic astrocytoma without IDH1 mutation and (4) glioblastoma without IDH1 mutation (p < 0.0001).
  • In this combined set of anaplastic astrocytomas and glioblastomas both, IDH1 mutation and IDH1 expression status were of greater prognostic relevance than histological diagnosis according to the current WHO classification system.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Glioma / classification. Glioma / genetics. Isocitrate Dehydrogenase / genetics. Mutation / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / pathology. Cohort Studies. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Young Adult


61. Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E: MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer; 2009 Sep 15;125(6):1407-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC.
  • Although the oncogenic and tumor suppressive functions of several miRNAs have been characterized, the role of miRNAs in mediating tumor invasion and migration remains largely unexplored.
  • Here, we performed real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays on 43 glioma samples (17 glioblastoma, 6 anaplastic astrocytoma, 10 low-grade astrocytoma, 6 oligodendroglioma and 4 ependymoma) and 6 glioma cell lines.
  • We found that miR-10b expression was upregulated in all glioma samples compared to non-neoplastic brain tissues.
  • The expression levels of miR-10b were associated with higher grade glioma.
  • Finally, multifocal lesions on enhanced MRI of 7 malignant gliomas were associated with higher expression levels of miR-10b (p = 0.02).
  • Our data indicated that miR-10b might play some role in the invasion of glioma cells.
  • [MeSH-major] Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic / physiology. Glioma / genetics. Membrane Glycoproteins / genetics. Receptors, Immunologic / genetics. Receptors, Urokinase Plasminogen Activator / genetics. rho GTP-Binding Proteins / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Up-Regulation

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • (PMID = 19536818.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LILRB2 protein, human; 0 / Membrane Glycoproteins; 0 / RHOC protein, human; 0 / RNA, Messenger; 0 / Receptors, Immunologic; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


62. Zhang L, Yamane T, Satoh E, Amagasaki K, Kawataki T, Asahara T, Furuya K, Nukui H, Naganuma H: Establishment and partial characterization of five malignant glioma cell lines. Neuropathology; 2005 Jun;25(2):136-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and partial characterization of five malignant glioma cell lines.
  • Five malignant glioma cell lines (YMG1, 2, 3, 4, and 5) were established from surgical specimens obtained from patients with glioblastoma or anaplastic astrocytoma, and these lines were partially characterized.
  • Three glioma cell lines (YMG1, 3, and 5) were weakly positive for GFAP by Western blot analysis and two cell lines were negative.
  • S-100 protein was positive in all glioma cell lines.
  • Fluorescence in situ hybridization analysis for EGFR gene expression did not show any amplification in the glioma cell lines.
  • Immunohistochemical studies revealed that the patterns of p53 and EGFR expressions in the original tumor tissues were mostly correlated with those in the malignant glioma cell lines.
  • These results suggest that the characteristics of p53 and EGFR expression in the malignant glioma cell lines were passed over from the original tumor tissues.
  • These newly established malignant glioma cell lines can be used for further analysis of the mechanisms of tumor growth and progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cell Line, Tumor. Gene Expression. Glioma / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cell Cycle Proteins / biosynthesis. Cyclin-Dependent Kinase 4. Cyclin-Dependent Kinase Inhibitor p15. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Cyclin-Dependent Kinases / biosynthesis. Female. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Proto-Oncogene Proteins / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis. S100 Proteins / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis. Tumor Suppressor Proteins / biosynthesis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875906.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN2B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Glial Fibrillary Acidic Protein; 0 / Proto-Oncogene Proteins; 0 / S100 Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


63. Yokota T, Kouno J, Adachi K, Takahashi H, Teramoto A, Matsumoto K, Sugisaki Y, Onda M, Tsunoda T: Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin. Acta Neuropathol; 2006 Jan;111(1):29-38
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin.
  • Glioblastoma multiforme (GBM), the most malignant class of glial neoplasm (grade IV in WHO criteria), carries the worst clinical prognosis among primary brain tumors in adults.
  • By comparing the profiles with those of normal brain tissue, we identified a number of differentially expressed genes: 54 with increased expression and 45 with reduced expression in GBMs.
  • To establish criteria for this diagnostic approach, we scored glial tumor tissues of different histological grades according to the staining results; the scores were significantly higher in anaplastic astrocytomas and GBMs than in diffuse astrocytomas or normal brain tissues.
  • These findings indicated that levels of these three proteins might serve as histological markers for malignant glioma classification.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Calcium-Binding Proteins / genetics. Cell Cycle Proteins / genetics. Dyneins / genetics. Glioblastoma / genetics. Guanine Nucleotide Exchange Factors / genetics

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16320026.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ARHGEF6 protein, human; 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / Guanine Nucleotide Exchange Factors; 0 / Rho Guanine Nucleotide Exchange Factors; 0 / SRI protein, human; EC 3.6.4.2 / Dyneins
  •  go-up   go-down


64. Guan X, Lai S, Lackey J, Shi J, Techavipoo U, Moulding HD, Flanders AE, Andrews DW: Revisiting anaplastic astrocytomas II: further characterization of an expansive growth pattern with visually enhanced diffusion tensor imaging. J Magn Reson Imaging; 2008 Dec;28(6):1322-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting anaplastic astrocytomas II: further characterization of an expansive growth pattern with visually enhanced diffusion tensor imaging.
  • PURPOSE: To seek to distinguish and visualize the different magnetic resonance imaging (MRI) growth patterns among malignant gliomas utilizing visually enhanced diffusion tensor imaging (DTI).
  • MATERIALS AND METHODS: Nineteen consecutive patients undergoing image-guided resection of a newly diagnosed malignant glioma underwent add-on acquisition of DTI data based on an Institutional Review Board (IRB)-approved imaging protocol during preoperative MRI scans for routine intraoperative image guidance.
  • Tumor growth patterns were assigned to expansive or mixed/infiltrative classes as described in the companion article (24).
  • DTI-based white matter tractography was conducted and the DTI data were fused with anatomical images using an in-house software package we developed to enhance the visualization of the tumor/fiber interface.
  • RESULTS: Out of the 19 tumor patients studied, 11 had infiltrative tumors and the other 8 had expansive tumors.
  • While less clear with 2D axial diffusion color maps, visually enhanced 3D reconstructions of the tumor/fiber interface successfully corroborated distinctive growth patterns.
  • This was particularly evident when viewed in 3D video loops of each tumor/fiber interface.
  • CONCLUSION: We have successfully developed software that visually enhances the anatomic details of the tumor/fiber interface in patients with anaplastic astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Image Processing, Computer-Assisted

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19025901.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Nomiya T, Nemoto K, Kumabe T, Takai Y, Yamada S: Prospective single-arm study of 72 Gy hyperfractionated radiation therapy and combination chemotherapy for anaplastic astrocytomas. BMC Cancer; 2008;8:11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective single-arm study of 72 Gy hyperfractionated radiation therapy and combination chemotherapy for anaplastic astrocytomas.
  • BACKGROUND: Despite intensive multimodal treatment, outcome of patients with malignant glioma remains poor, and a standard dose of radiotherapy for anaplastic astrocytoma has not been defined.
  • In the past RTOG study (83-02), the arm of 72 Gy hyperfractionated radiotherapy (HFRT) for malignant gliomas showed better outcome than the arms of higher doses (76.8 - 81.6 Gy) and the arms of lower doses (48 - 54.4 Gy).
  • METHODS: From July 1995, 44 consecutive eligible patients with histologically proven anaplastic astrocytoma were enrolled in this study (HFRT group).
  • One (2%) of the patients clinically diagnosed as brain necrosis due to radiation therapy.
  • CONCLUSION: The results of this study suggested that 72 Gy HFRT seemed to show favorable outcome for patients with anaplastic astrocytoma with tolerable toxicity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Nimustine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 Aug;177(8):424-31 [11544905.001]
  • [Cites] Radiother Oncol. 1999 Apr;51(1):27-33 [10386714.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):338-43 [3339397.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Mar;18(3):569-75 [2318689.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):275-80 [2168352.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):119-26 [1512147.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):193-207 [8380567.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 May 20;26(2):239-44 [8387988.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):627-36 [8226158.001]
  • [Cites] Radiat Med. 1993 Jul-Aug;11(4):146-53 [8234858.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1535-43 [8608540.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1163-7 [8985039.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):57-63 [9422558.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):79-88 [9989517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):287-92 [10030251.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):58-66 [12007942.001]
  • (PMID = 18199339.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0S726V972K / Nimustine
  • [Other-IDs] NLM/ PMC2254433
  •  go-up   go-down


66. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B: MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer; 2009 Jan;45(1):146-53
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
  • AIMS: To investigate the correlation between O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and benefit from temozolomide in patients with recurrent high-grade glioma.
  • RESULTS: A subgroup of 38 patients who were chemotherapy-naive at recurrence was analysed (22 glioblastoma, 12 anaplastic astrocytoma [AA] and 4 anaplastic oligoastrocytoma [AOA]); none had 1p/19q loss.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18945611.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


67. Yang SH, Hong YK, Yoon SC, Kim BS, Lee YS, Lee TK, Lee KS, Jeun SS, Kim MC, Park CK: Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma. Oncol Rep; 2007 Jun;17(6):1359-64
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
  • We analyzed the clinical efficacy and toxicity of concurrent therapy as a first line modality for malignant glioma patients.
  • From 1998 to 2004, 39 patients, 22 with glioblastoma (GM), nine with anaplastic astrocytoma (AA), 7 with anaplastic oligodendroglioma (AO) and 1 with anaplastic oligodendro-astrocytoma (AOA) were enrolled in this study.
  • The median interval from the completion of radiotherapy to the diagnosis of necrosis was 19 weeks.
  • Modified concurrent chemoradiotherapy may be a feasible option for treating malignant glioma with acceptable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brain Neoplasms / drug therapy. Glioma / drug therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487391.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


68. Schiff D: Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation. Cancer Invest; 2007 Dec;25(8):776-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy
  • [MeSH-minor] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Clinical Trials, Phase III as Topic. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Humans. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952745.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Number-of-references] 60
  •  go-up   go-down


69. Montemor JP, Peria FM, Monti CR, Petrilli LS, Colli BO, Carlotti Júnior CG: Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment. Onkologie; 2008 Sep;31(8-9):435-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment.
  • BACKGROUND: Anaplastic astrocytomas (AA) and glioblastomas (GB) are the most common malignant gliomas, and despite newly developed drugs and combined treatments, they still have an adverse prognosis.
  • Paclitaxel is a cytotoxic agent with radiosensitizing properties and exerts objective growth inhibition in glioma tumor cells.
  • CONCLUSIONS: Chemoradiotherapy with weekly paclitaxel is safe and tolerable although there was no increase in the overall survival and 12-month survival of malignant glioma patients.
  • Further investigations modulating the paclitaxel entrance and delivery into the brain should be encouraged.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioma / drug therapy. Glioma / radiotherapy. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18787350.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


70. Ueda R, Low KL, Zhu X, Fujita M, Sasaki K, Whiteside TL, Butterfield LH, Okada H: Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J Transl Med; 2007 Dec 19;5:68
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma.
  • BACKGROUND: In patients with high grade glioma, little is known regarding existence of naturally occurring adaptive T cell reactivity against glioma-associated antigens (GAAs).
  • In this report, we characterized GAA-specific CD8+ T cells and innate immune cells in a patient who has survived with anaplastic astrocytoma (AA) for over 12 years without recurrence.
  • RESULTS: The patient's tumor expressed both EphA2 and IL-13Ralpha2, and in vitro stimulated PBMC demonstrated superior EphA2883-891 and IL-13Ralpha2345-353-specific CTL reactivity compared to PBMC samples from two other patients with progressing malignant glioma.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):577-83 [10649250.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4946-52 [10987311.001]
  • [Cites] J Cell Biol. 2001 Mar 5;152(5):971-84 [11238453.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):909s-916s [11300491.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2851-5 [12231526.001]
  • [Cites] Brain Res Brain Res Rev. 2003 May;42(2):97-122 [12738053.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8874-9 [12847287.001]
  • [Cites] J Immunol. 2003 Nov 1;171(9):4927-33 [14568975.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6946-55 [15501973.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1641-50 [9802976.001]
  • [Cites] Nat Med. 1999 Jun;5(6):677-85 [10371507.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4050-5 [10463606.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):8062-7 [15520217.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):450-5 [15688371.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):6863-71 [15905528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6 [15980149.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):717-22 [16207473.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4943-51 [16651452.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5883-91 [16740728.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] J Invest Dermatol. 2007 Mar;127(3):622-9 [17039243.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1842-52 [17293384.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1204-12 [17476350.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):203-14 [17541944.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Nat Med. 2007 Sep;13(9):1050-9 [17704786.001]
  • [Cites] Cancer Immunol Immunother. 2007 Dec;56(12):1931-43 [17522860.001]
  • (PMID = 18093336.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100327; United States / NINDS NIH HHS / NS / P01 NS040923; United States / NINDS NIH HHS / NS / P01 NS40923
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen
  • [Other-IDs] NLM/ PMC2244605
  •  go-up   go-down


71. Yoshikawa K, Saito K, Kajiwara K, Nomura S, Ishihara H, Suzuki M: CyberKnife stereotactic radiotherapy for patients with malignant glioma. Minim Invasive Neurosurg; 2006 Apr;49(2):110-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CyberKnife stereotactic radiotherapy for patients with malignant glioma.
  • The authors report on their experience using the CyberKnife in 25 patients with malignant gliomas.
  • METHODS: Twenty-five patients with histologically proven malignant gliomas (18 glioblastoma: GB, 7 anaplastic astrocytoma: AA) were treated with the CyberKnife at Konan St. Hill Hospital between June 1998 and November 2002.
  • Patient-, tumor-, and treatment-related variables were analyzed by univariate analysis, and survival curves were generated by the Kaplan-Meier product limit.
  • RESULTS: In the 18 GB patients, the median survival after diagnosis was 20.7 months (82.6 weeks) with a mean follow-up of 85.7 weeks.
  • Patients younger than 70 years had a median survival after diagnosis of 37.1 months, compared to 12.4 months for older patients (p = 0.003).
  • Similarly, patients with well-controlled lesions had a median survival after diagnosis of 39.8 months compared to 16.0 months for those with uncontrolled lesions (p = 0.031).
  • CONCLUSION: This is the first report of CyberKnife stereotactic radiotherapy applied to the treatment of malignant gliomas.
  • The frameless and painless CyberKnife stereotactic radiotherapy has the potential to be as useful for treatment of malignant glioma as other radiosurgical modalities.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / pathology. Radiosurgery / instrumentation. Robotics

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708341.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


72. Su YW, Chang MC, Chiang MF, Hsieh RK: Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol; 2005 Feb;71(3):315-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
  • In patients with recurrent malignant glioma, treatment-related myelodysplastic syndrome (t-MDS) and acute leukemia are rare adverse effects because the median survival after relapse is limited.
  • We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ).
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Leukemia / chemically induced. Myelodysplastic Syndromes / chemically induced. Neoplasm Recurrence, Local / drug therapy


73. Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA: Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol; 2006 Oct;80(1):83-90
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
  • PURPOSE: Since anaplastic gliomas (AG) depend on matrix metalloproteinases for tumor cell invasion and angiogenesis, we undertook this phase II study to evaluate the matrix metalloproteinase inhibitor marimastat (MT), combined with the alkylator temozolomide (TMZ) in patients with recurrent AG, looking for improved outcomes.
  • Results were compared to our database of anaplastic glioma patients treated at recurrence.
  • [MeSH-major] Anticonvulsants / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Joint Diseases / chemically induced. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Joint Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639492.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Enzyme Inhibitors; 0 / Hydroxamic Acids; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9035-51-2 / Cytochrome P-450 Enzyme System; D5EQV23TDS / marimastat
  •  go-up   go-down


74. Vordermark D, Kölbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer; 2005;5:55
Hazardous Substances Data Bank. TENIPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma.
  • BACKGROUND: Hypofractionated stereotactic radiotherapy (HFSRT) is one salvage treatment option in previously irradiated patients with recurrent malignant glioma.
  • METHODS: Between 1997 and 2003, 19 patients with recurrent malignant glioma (14 glioblastoma on most recent histology, 5 anaplastic astrocytoma) were treated with HFSRT.
  • Median time to tumor progression after HFSRT on imaging was 4.9 months (1.3 to 37.3) months.
  • [MeSH-major] Brain Neoplasms / surgery. Dose Fractionation. Glioma / surgery. Radiosurgery / methods. Radiotherapy / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):155-9 [10776976.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6):606-11 [12478010.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2678-86 [14669289.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Bull Cancer. 2004 Nov;91(11):883-9 [15582893.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] Radiother Oncol. 1999 Oct;53(1):53-7 [10624854.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):226-9 [9167741.001]
  • [Cites] Radiother Oncol. 1997 Oct;45(1):83-8 [9364636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):293-8 [10030252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8 [9069312.001]
  • (PMID = 15924621.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0S726V972K / Nimustine; 957E6438QA / Teniposide
  • [Other-IDs] NLM/ PMC1156875
  •  go-up   go-down


75. Grommes C, Conway DS, Alshekhlee A, Barnholtz-Sloan JS: Inverse association of PPARγ agonists use and high grade glioma development. J Neurooncol; 2010 Nov;100(2):233-9
Hazardous Substances Data Bank. ROSIGLITAZONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverse association of PPARγ agonists use and high grade glioma development.
  • In a retrospective chart review, we assessed the influence of PPARγ agonists on the odds of having a high grade glioma.
  • We reviewed patients with a diagnosis of anaplastic astrocytoma and glioblastoma multiforme (GBM) between 1999 and 2008.
  • Multivariable unconditional logistic regression models were used to calculate the odds of diabetic hip fracture patients using a PPARγ agonist at time of diagnosis as compared to diabetic glioma patients.
  • We identified 1602 hip fracture patients and 302 high grade glioma patients, 15 and 16% were diabetics, respectively.
  • PPARγ agonists were used by 20% of diabetic hip fracture patients and by 6% of high grade glioma patients (chi-square P-value = 0.02) with an odds ratio of 4.081 (95% CI: 1.119-14.881).
  • The prevalence of PPARγ agonist use was lower in the diabetic high grade glioma group when compared to diabetic hip fracture patients.
  • These findings suggest that diabetic high grade glioma patients are not given PPARγ agonists as often as diabetic hip fracture patients even though these drugs are considered standard of care and should be equally distributed throughout both groups.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. PPAR gamma / agonists

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. PIOGLITAZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20443132.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / PPAR gamma; 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone; X4OV71U42S / pioglitazone
  •  go-up   go-down


76. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS: Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer; 2005 Jan 15;103(2):329-38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
  • BACKGROUND: In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease.
  • RESULTS: Thirty-four of the 37 patients enrolled in the current study (92%) were diagnosed with recurrent GBM and 3 patients (8%) were diagnosed with recurrent anaplastic astrocytoma (AA).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15558802.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA096890; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / M01 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; 7673326042 / irinotecan; JCX84Q7J1L / Celecoxib; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


77. Shervington A, Patel R, Lu C, Cruickshanks N, Lea R, Roberts G, Dawson T, Shervington L: Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res; 2007 Feb 23;1134(1):45-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma.
  • Although scientific advances have recognised the prognostic power of telomerase activity in different cancers, as yet there has been no investigation regarding the expression variation of telomerase subunits in glioma tissues and cell lines.
  • In this study, a recurrent anaplastic ependymoma and seven glioblastoma biopsy samples, four cell lines and four controls including two normal brain tissues were analysed for telomerase subunit expression profiles together with telomerase activity.
  • TEP1 was expressed in all glioma cell lines and 70% of glioblastoma tissues, in addition to the control brain tissues.
  • Tankyrase was expressed in 85% of the glioblastoma tissues and was down-regulated in the recurrent anaplastic ependymoma tissue control cell lines.
  • Dyskerin was expressed in all cell lines and tissues apart from U87-MG and NHA cells and the recurrent anaplastic ependymoma tissue.
  • As expected, PARP1 and GAPDH showed constitutive expression throughout all cell lines and tissues since both are known to be housekeeping genes. hTERT was expressed in all glioma cell lines and tissues but was absent in the control cells and tissues.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Glioma / enzymology. Glioma / genetics. Telomerase / genetics
  • [MeSH-minor] Biopsy. Carrier Proteins / genetics. Cell Cycle Proteins / genetics. Cell Line, Tumor. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Gene Expression Regulation, Neoplastic / genetics. Humans. Nuclear Proteins / genetics. Tankyrases / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196947.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cell Cycle Proteins; 0 / DKC1 protein, human; 0 / Nuclear Proteins; 0 / TEP1 protein, human; EC 2.4.2.30 / Tankyrases; EC 2.4.4.30 / TNKS protein, human; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


78. Oshiro S, Tsugu H, Komatsu F, Ohnishi H, Ueno Y, Sakamoto S, Fukushima T, Soma G: Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma. Anticancer Res; 2006 Nov-Dec;26(6A):4027-32
Genetic Alliance. consumer health - Glioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma.
  • BACKGROUND: This study assessed safety and efficacy for intratumoral administration of tumor necrosis factor-a (TNF-SAM2) into the post-operative tumor cavity through an Ommaya reservoir for patients with malignant glioma.
  • MATERIALS AND METHODS: Seven patients with malignant glioma, comprising 3 cases with glioblastoma multiforme (GBM), 3 cases with anaplastic astrocytoma (AA) and 1 case with malignant ependymoma (ME) were included in the study.
  • TNF-SAM2 was administrated into the post-operative tumor cavity through a reservoir at a concentration of 1x10(4) U/body when recurrence was detected, or as initial induction therapy concomitant with radiotherapy.
  • RESULTS: Partial response to this regional immunotherapy was seen in 4 out of 7 patients, and 1 patient with GBM has remained clinically stable for >184 weeks without tumor progression.
  • With AA, 2 cases appeared to display slowed advance and longer times to tumor recurrence or regrowth.
  • No serious adverse effects, such as brain edema, hemorrhage or seizure were observed, nor systemic toxicities.
  • CONCLUSION: Local immunotherapy with TNF-SAM2 may safely contribute to therapeutic efficacy in some patients with malignant glioma.
  • [MeSH-major] Glioma / therapy. Tumor Necrosis Factor-alpha / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195453.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / TNF-SAM2; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


79. Higgins SC, Pilkington GJ: The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma. Anticancer Res; 2010 Feb;30(2):391-7
Hazardous Substances Data Bank. AMITRIPTYLINE HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma.
  • BACKGROUND: In this investigation the effects of tricyclic drugs on cellular respiration were studied using the anaplastic astrocytoma cell line IPSB-18 by use of a Clark-type oxygen electrode which measured changes in cellular respiration rate (oxygen consumption), in a dose-response assay.
  • Overall, it appeared that clomipramine and its metabolite norclomipramine were the most potent inhibitors of cellular respiration in glioma cells over the concentration range 0.5-0.9 mM.
  • Dexamethasone was able to induce inhibition of cellular respiration both alone in glioma cells, and in combination with clomipramine, where it had an additive or synergistic effect, thereby increasing cell death.
  • [MeSH-major] Antidepressive Agents, Tricyclic / pharmacology. Antineoplastic Agents, Hormonal / pharmacology. Astrocytoma / metabolism. Brain Neoplasms / metabolism. Cell Respiration / drug effects. Dexamethasone / pharmacology
  • [MeSH-minor] Amitriptyline / pharmacology. Antineoplastic Combined Chemotherapy Protocols. Clomipramine / pharmacology. Doxepin / pharmacology. Humans. Oxygen Consumption / drug effects. Respiratory Rate. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXEPIN .
  • Hazardous Substances Data Bank. Clomipramine .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332444.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antidepressive Agents, Tricyclic; 0 / Antineoplastic Agents, Hormonal; 1668-19-5 / Doxepin; 1806D8D52K / Amitriptyline; 7S5I7G3JQL / Dexamethasone; NUV44L116D / Clomipramine
  •  go-up   go-down


80. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B: Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther; 2006 Mar;5(1):40-7
Hazardous Substances Data Bank. Glutamine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.
  • BACKGROUND: Brainstem glioma carries the worst prognosis of all malignancies of the brain.
  • Most patients with brainstem glioma fail standard radiation therapy and chemotherapy and do not survive longer than 2 years.
  • Treatment is even more challenging when an inoperable tumor is of high-grade pathology (HBSG).
  • PATIENTS: The following group of 18 patients was evaluable: 4 patients with glioblastomas and 14 patients with anaplastic HBSG.
  • RESULTS: The overall survival at 2 and 5 years was 39% and 22%, respectively, and maximum survival was more than 17 years for a patient with anaplastic astrocytoma and more than 5 years for a patient with glioblastoma.
  • CONCLUSION: Antineoplastons contributed to more than a 5-year survival in recurrent diffuse intrinsic glioblastomas and anaplastic astrocytomas of the brainstem in a small group of patients.
  • [MeSH-major] Benzeneacetamides / administration & dosage. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Glutamine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Phenylacetates / administration & dosage. Piperidones / administration & dosage

  • Genetic Alliance. consumer health - Glioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484713.001).
  • [ISSN] 1534-7354
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzeneacetamides; 0 / Drug Combinations; 0 / Phenylacetates; 0 / Piperidones; 0RH81L854J / Glutamine; 104624-98-8 / antineoplaston AS 2-1; 91531-30-5 / antineoplaston A10
  •  go-up   go-down


81. Jin M, Komohara Y, Shichijo S, Yamanaka R, Nikawa J, Itoh K, Yamada A: Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients. Cancer Sci; 2008 Aug;99(8):1656-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients.
  • In the present study, we examined the expression of the EphB6 variant (EphB6v) in a panel of brain tumor cell lines and glioblastoma tissues and we found that EphB6v was preferentially expressed in malignant brain tumors, such as glioblastomas and anaplastic astrocytomas.
  • The two EphB6v-derived peptides exhibited the ability to bind to human leukocyte antigen (HLA)-A0201 molecules, and each of them was able to induce cytotoxic T lymphocytes in vitro in the peripheral blood mononuclear cells of HLA-A2(+) glioma patients.
  • [MeSH-minor] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Case-Control Studies. Cell Line, Tumor. Gene Expression. Glioblastoma / metabolism. HLA-A Antigens. HLA-A2 Antigen. Hepatocytes. Humans

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754880.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; EC 2.7.1.- / EPHB6 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


82. Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, Xie K, Huang S: FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res; 2008 Nov 1;68(21):8733-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells.
  • We previously found that FoxM1B is overexpressed in human glioblastomas and that forced FoxM1B expression in anaplastic astrocytoma cells leads to the formation of highly angiogenic glioblastoma in nude mice.
  • However, the molecular mechanisms by which FoxM1B enhances glioma angiogenesis are currently unknown.
  • FoxM1B overexpression increased VEGF expression, whereas blockade of FoxM1 expression suppressed VEGF expression in glioma cells.
  • Transfection of FoxM1 into glioma cells directly activated the VEGF promoter, and inhibition of FoxM1 expression by FoxM1 siRNA suppressed VEGF promoter activation.
  • Furthermore, FoxM1 overexpression increased and inhibition of FoxM1 expression suppressed the angiogenic ability of glioma cells.
  • Our findings provide both clinical and mechanistic evidence that FoxM1 contributes to glioma progression by enhancing VEGF gene transcription and thus tumor angiogenesis.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Feb;92(2):326-33 [10659021.001]
  • [Cites] Genes Dev. 2008 Feb 15;22(4):449-62 [18258752.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5879-86 [11059786.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4143-54 [11358838.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2058-65 [11960378.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):125-34 [12107097.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8404-13 [12466961.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] Semin Cancer Biol. 2004 Apr;14(2):123-30 [15018896.001]
  • [Cites] Genes Dev. 2004 Apr 1;18(7):830-50 [15082532.001]
  • [Cites] BMC Cancer. 2003 Sep 17;3:23 [13678425.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):941-51 [15184909.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Oct;15(5):297-324 [15450248.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Jan;53(1):11-21 [8301315.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):13333-40 [7768934.001]
  • [Cites] Circ Res. 1995 Sep;77(3):638-43 [7641334.001]
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5363-8 [7565686.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Pediatr Neurosurg. 1996;24(1):41-9 [8817614.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1626-41 [9032290.001]
  • [Cites] Nucleic Acids Res. 1997 May 1;25(9):1715-9 [9108152.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19827-36 [9242644.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3860-4 [9288800.001]
  • [Cites] Mol Biol Cell. 1998 Feb;9(2):469-81 [9450968.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):118-24 [10077162.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):162-7 [10328589.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):126-36 [15654331.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2065-9 [15781613.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):202-13 [15688401.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):134-53 [15831232.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22278-86 [15817462.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5181-9 [15958562.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1712-20 [16452231.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2153-61 [16489016.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3593-602 [16585184.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1420-31 [17408638.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8293-300 [17804744.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6212-9 [17404569.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2562-72 [10873113.001]
  • (PMID = 18974115.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA116528-03; United States / NCI NIH HHS / CA / CA116528-03; United States / NCI NIH HHS / CA / R01-CA-116528; United States / NCI NIH HHS / CA / R01 CA116528; United States / NCI NIH HHS / CA / R01 CA116528-02; United States / NCI NIH HHS / CA / CA116528-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / FOXM1 protein, human; 0 / Forkhead Transcription Factors; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ NIHMS67455; NLM/ PMC2597644
  •  go-up   go-down


83. Cooper PB, Auerbach A, Aguilera NS, Adair C, Moores L, Geyer D, Rushing EJ: Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature. Clin Neuropathol; 2006 Sep-Oct;25(5):232-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature.
  • OBJECTIVE AND IMPORTANCE: Isolated anaplastic large cell lymphoma (ALCL) presenting in the primary central nervous system is distinctly uncommon.
  • There appeared to be a clear demarcation between white matter and tumor with no obvious necrosis.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / analysis. Combined Modality Therapy. Diagnosis, Differential. Glioma / pathology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Radiotherapy. Seizures / etiology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Neuropathol. 2007 Jan-Feb;26(1):39-40; author reply 40 [17290938.001]
  • (PMID = 17007446.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


84. Momota H, Narita Y, Miyakita Y, Hosono A, Makimoto A, Shibui S: Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. Pediatr Blood Cancer; 2010 Sep;55(3):577-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.
  • We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ).
  • Although alkylating agents such as TMZ are known to induce secondary hematologic malignancy, only several cases of treatment-related acute leukemia have been reported after TMZ-alone chemotherapy for malignant gliomas.
  • We demonstrate a rare case of TMZ-related ALL in a child with glioma possibly associated with a germline TP53 mutation.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Frontal Lobe. Genes, p53 / genetics. Germ-Line Mutation. Neoplasms, Second Primary / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • [ErratumIn] Pediatr Blood Cancer. 2011 Mar;56(3):509. Nariata, Yoshitaka [corrected to Narita, Yoshitaka]
  • (PMID = 20658636.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


85. Perry J, Laperriere N, Zuraw L, Chambers A, Spithoff K, Cairncross JG, Neuro-oncology Disease Site Group, Cancer Care Ontario Program in Evidence-Based Care: Adjuvant chemotherapy for adults with malignant glioma: a systematic review. Can J Neurol Sci; 2007 Nov;34(4):402-10
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for adults with malignant glioma: a systematic review.
  • OBJECTIVE: This systematic review examines the role of chemotherapy following surgery and external beam radiotherapy for adults with newly diagnosed malignant glioma.
  • RESULTS: Two RCTs reported a survival advantage in favour of radiotherapy with concomitant and adjuvant temozolomide compared with radiotherapy alone in patients with anaplastic astrocytoma or glioblastoma.
  • Temozolomide may be considered in other situations (i.e., ECOG 2, biopsy only, age > 70, intermediate grade glioma), but there is no high-level evidence to support this decision.
  • Adjuvant chemotherapy may be an option for younger patients with anaplastic (grade 3) astrocytoma and patients with pure or mixed oligodendroglioma.
  • The combination of procarbazine, lomustine, and vincristine (PCV) is not recommended for patients with anaplastic oligodendroglioma and oligoastrocytoma.
  • [MeSH-major] Brain Neoplasms / drug therapy. Glioma / drug therapy

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18062446.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Canada
  • [Number-of-references] 37
  •  go-up   go-down


86. Choi JD, Powers CJ, Vredenburgh JJ, Friedman AH, Sampson JH: Cryptococcal meningitis in patients with glioma: a report of two cases. J Neurooncol; 2008 Aug;89(1):51-3
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cryptococcal meningitis in patients with glioma: a report of two cases.
  • OBJECTIVE AND IMPORTANCE: We describe two patients with high-grade glioma undergoing treatment with corticosteroids and chemotherapy who presented with cryptococcal meningitis and sepsis.
  • A 33-year-old man with a history of anaplastic astrocytoma, on dexamethasone and status post radiation therapy, four cycles of temozolomide and two cycles of Lomustine (CCNU), presented with headache, dizziness and photophobia and was found to have CSF and blood cultures positive for Cryptococcus neoformans.
  • CONCLUSION: Patients with high-grade glioma treated with long-term corticosteroid therapy and chemotherapy are at increased risk of developing opportunistic infections.
  • [MeSH-major] Brain Neoplasms / complications. Dexamethasone / adverse effects. Glioma / complications. Immunosuppression / adverse effects. Meningitis, Cryptococcal / chemically induced. Opportunistic Infections / chemically induced

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398572.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antifungal Agents; 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 7S5I7G3JQL / Dexamethasone; 7XU7A7DROE / Amphotericin B; 85622-93-1 / temozolomide; 8VZV102JFY / Fluconazole; D83282DT06 / Flucytosine
  •  go-up   go-down


87. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Walker A, Friedman HS: Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol; 2009 Mar 10;27(8):1262-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
  • PURPOSE: This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide.
  • PATIENTS AND METHODS: Patients were accrued into two independent strata on the basis of histology: glioblastoma multiforme (GBM) and anaplastic glioma.
  • One of 34 patients (3%) with GBM (95% CI, 0.1% to 15%) and five of 32 assessable patients (16%) with anaplastic glioma (95% CI, 5% to 33%) were responders.
  • CONCLUSION: O(6)-BG when added to a 1-day dosing regimen of temozolomide was able to restore temozolomide sensitivity in patients with temozolomide-resistant anaplastic glioma, but there seemed to be no significant restoration of temozolomide sensitivity in patients with temozolomide-resistant GBM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):85-9 [17031555.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3367-72 [1647266.001]
  • [Cites] Br J Cancer. 1993 Jun;67(6):1299-302 [8512814.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):471-6 [8258196.001]
  • [Cites] J Neurooncol. 1994;21(2):135-40 [7861189.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):482-90 [8595163.001]
  • [Cites] Br J Cancer. 1996 May;73(9):1049-52 [8624262.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3310-5 [9779706.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):735-41 [9816224.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3851-7 [9850030.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7646-53 [16234526.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):399-404 [17264335.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • (PMID = 19204199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / R37 CA 011898-38; United States / NCI NIH HHS / CA / R21 CA101298; United States / NINDS NIH HHS / NS / 5P50 NS20023-25; United States / NCI NIH HHS / CA / 5P50 CA 108786-4; United States / NCRR NIH HHS / RR / RR024126; United States / NCI NIH HHS / CA / 1 R21 CA 101298-01; United States / NCRR NIH HHS / RR / TL1 RR024126; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 01KC87F8FE / O(6)-benzylguanine; 5Z93L87A1R / Guanine; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  • [Other-IDs] NLM/ PMC2667825
  •  go-up   go-down


88. Roessler K, Gatterbauer B, Becherer A, Paul M, Kletter K, Prayer D, Hoeftberger R, Hainfellner J, Asenbaum S, Knosp E: Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg; 2007 Oct;50(5):273-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation.
  • OBJECTIVE: The objective of this study was to investigate the histological correlate of (11)C-methionine (MET) PET uptake of brain gliomas by image fusion for navigated surgery.
  • RESULTS: MET PET tumor uptake was detected in 26 of 27 patients (96.3%).
  • The quantitative MET tumor standardized uptake value (SUV) ratio was significantly higher in malignant gliomas and oligodendrogliomas than in low-grade gliomas (2.76/2.62 vs. 1.67, p=0.03).
  • Focal uptake corresponded to malignant glioma histology in 66.7%, and uniform global uptake to oligodendroglial histology in 72.7%.
  • In oligodendrogliomas, global MET uptake constituted 81.5% (range 53.8-135%) of the MRI T(1) tumor volume on average and was limited to the MRI FLAIR tumor volume in 86% (7/8) of patients.
  • Tissue samples of focal MET uptake areas correlated with histological anaplasia in 66.6% (8/12 glioma patients), although 62.5% (5/8 patients) lacked MRI contrast enhancement.
  • CONCLUSION: MET PET image fusion may facilitate the targeting of anaplastic foci in homogeneous MRI non-enhancing gliomas for biopsy, may identify oligodendroglial histology preoperatively as well as characterize biologically active tumor volumes within MRI T(1)/FLAIR tumor areas of candidate patients for resection.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Brain Neoplasms / surgery. Glioma / radionuclide imaging. Glioma / surgery. Neuronavigation / methods. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Carbon Radioisotopes. Child. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted / instrumentation. Image Processing, Computer-Assisted / methods. Male. Methionine / metabolism. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / surgery. Predictive Value of Tests. Preoperative Care / instrumentation. Preoperative Care / methods. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058643.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


89. Tanaka M, Ino Y, Nakagawa K, Tago M, Todo T: High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. Lancet Oncol; 2005 Dec;6(12):953-60
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison.
  • BACKGROUND: Although radiotherapy remains the main postoperative treatment for patients with malignant glioma, modifications to regimens have not improved the poor outlook of patients with this disease.
  • We aimed to investigate whether high-dose conformal radiotherapy improves the survival of patients with supratentorial malignant glioma compared with conventional radiotherapy.
  • METHODS: 29 patients with anaplastic astrocytoma and 61 patients with glioblastoma who received high-dose conformal radiotherapy during 1990-2002 were compared with 34 patients with anaplastic astrocytoma and 60 patients with glioblastoma who received conventional 60 Gy radiotherapy during 1979-89.
  • FINDINGS: Patients who received high-dose radiotherapy had significantly longer overall survival compared with those who received conventional radiotherapy (adjusted hazard ratio 0.30 [95% CI 0.12-0.76], p=0.011 for anaplastic astrocytoma and 0.49 [0.28-0.87], p=0.014 for glioblastoma).
  • Patients with anaplastic astrocytoma in the high-dose group have not yet reached median survival; median survival in the conventional radiotherapy group was 22.3 months (95% CI 20.6-24.0).
  • INTERPRETATION: High-dose, standard-fractionated radiotherapy shows potential as the main postoperative treatment for patients with supratentorial malignant glioma.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Radiotherapy, Conformal

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2005 Dec;6(12):915-6 [16321754.001]
  • (PMID = 16321763.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


90. De Witt Hamer PC, Van Tilborg AA, Eijk PP, Sminia P, Troost D, Van Noorden CJ, Ylstra B, Leenstra S: The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene; 2008 Mar 27;27(14):2091-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids.
  • We obtained genomic profiles by array comparative genomic hybridization of both short- and long-term primary cell and spheroid cultures, derived from seven glioblastomas and one anaplastic oligodendroglioma.
  • It is concluded that genomic profiles of primary cell cultures from glioblastoma are frequently deviant from parental tumor profiles, whereas spheroids are genetically more representative of the glioblastoma.
  • This implies that glioma cell culture data have to be handled with the highest caution.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Aberrations. Glioblastoma / genetics. Spheroids, Cellular / metabolism
  • [MeSH-minor] Cell Culture Techniques. Genomics. Humans. Oligonucleotide Array Sequence Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17934519.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


91. Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF: Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol; 2010 Apr 20;28(12):2051-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
  • PATIENTS AND METHODS Patients with malignant glioma at progression after standard TMZ 150 to 200 mg/m(2) x 5 days in a 28-day cycle for three or more cycles were stratified by tumor type (anaplastic glioma group A, GBM, group B).
  • For patients with anaplastic glioma, 6-month PFS was 35.7%; 1-year survival was 60.7%.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioma / drug therapy


92. Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, Fisher JD, New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol; 2008 Aug;10(4):617-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.
  • Atrasentan is an oral selective endothelin-A receptor antagonist that may inhibit cell proliferation and interfere with angiogenesis during glioma growth.
  • Patients with recurrent malignant glioma received oral atrasentan at >or=10 mg/day.
  • Patients were evaluated for response every 8 weeks and remained on the study until the tumor progressed or toxicities occurred.
  • Twenty-two patients had glioblastoma multiforme (GBM), 2 had anaplastic astrocytoma, and 1 had an anaplastic oliogodendroglioma; 24 patients had received one prior chemo therapy regimen before being enrolled in the study.
  • We conclude that the MTD of daily oral atrasentan in patients with recurrent malignant glioma is 70 mg/day.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Br J Clin Pharmacol. 2000 Jun;49(6):562-73 [10848720.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Br J Clin Pharmacol. 2002 Apr;53(4):355-62 [11966665.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]
  • [Cites] Nat Rev Drug Discov. 2002 Dec;1(12):986-1001 [12461520.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):679-89 [12586806.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2965-72 [12912943.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4406-11 [15240529.001]
  • [Cites] Cancer Chemother Rep. 1974 Nov-Dec;58(6):787-92 [4447922.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Peptides. 1993 Mar-Apr;14(2):385-99 [8483816.001]
  • [Cites] J Neurochem. 1994 Dec;63(6):2240-7 [7964744.001]
  • [Cites] J Cardiovasc Pharmacol. 1995;26 Suppl 3:S408-11 [8587429.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Feb;276(2):473-81 [8632312.001]
  • [Cites] Biochim Biophys Acta. 1996 May 28;1311(3):155-63 [8664342.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Apr;56(4):435-9 [9100674.001]
  • [Cites] N Engl J Med. 1998 Mar 19;338(12):784-90 [9504938.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Circulation. 1998 Nov 24;98(21):2262-8 [9826312.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):32-40 [15701280.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • (PMID = 18477765.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062406; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA62406; United States / NCI NIH HHS / CA / UO1 CA-62475
  • [Publication-type] Case Reports; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyrrolidines; V6D7VK2215 / atrasentan
  • [Other-IDs] NLM/ PMC2666236
  •  go-up   go-down


93. Patel R, Shervington L, Lea R, Shervington A: Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma. Brain Res; 2008 Jan 10;1188:173-81
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma.
  • While treatment with 5azadC downregulated hTERT and upregulated MGMT expression in two glioma cell lines, there was no change in the expression of these two genes in the normal cell line.
  • To further evaluate the effect of these findings, the level of hTERT and MGMT expression was measured in a recurrent anaplastic ependymoma, seven glioblastoma and two normal brain tissues.
  • While four of eight gliomas and one of the normal tissues expressed MGMT, hTERT was expressed in all gliomas but not in the normal brain tissue.
  • Results of this study suggest that taxol together with 5azadC may be a good therapeutic combination for glioma.
  • In addition, the work on cell lines can be repeated on tissues utilizing hTERT as the therapeutic target for demethylation using 5azadC in glioma.
  • [MeSH-major] Azacitidine / analogs & derivatives. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Gene Silencing / drug effects. Glioma / drug therapy. Glioma / genetics. Telomerase / genetics
  • [MeSH-minor] Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / pharmacology. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Aging / drug effects. Cell Aging / genetics. Cell Line, Tumor. DNA Methylation / drug effects. Dose-Response Relationship, Drug. Down-Regulation / drug effects. Down-Regulation / genetics. Drug Resistance, Neoplasm / drug effects. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Enzymologic / genetics. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Methyltransferases / antagonists & inhibitors. Methyltransferases / metabolism. Paclitaxel / pharmacology. Paclitaxel / therapeutic use. RNA, Messenger / drug effects. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021753.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / RNA, Messenger; 776B62CQ27 / decitabine; EC 2.1.1.- / Methyltransferases; EC 2.7.7.49 / Telomerase; M801H13NRU / Azacitidine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


94. Chu SH, Ma YB, Zhang H, Feng DF, Zhu ZA, Li ZQ, Yuan XH: Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells. J Neurooncol; 2007 Oct;85(1):33-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells.
  • Hepatocyte growth factor (HGF) is a pleiotrophic cytokine that stimulates motility and invasion of several cancer cell types and induces angiogenesis, which is known to be expressed in several malignancies including glioma.
  • The effect of transforming growth factor-beta (TGF-beta) isoforrns as well as gangliosides on HGF production was investigated in human glioma cell lines.
  • The ganglioside GD3 enhanced this release to the greatest extent and the stimulation was more marked in a glioblastoma cell line than in the two other anaplastic astrocytoma cell lines.
  • [MeSH-major] Brain Neoplasms / metabolism. Gangliosides / pharmacology. Glioma / metabolism. Hepatocyte Growth Factor / biosynthesis. Transforming Growth Factor beta / pharmacology
  • [MeSH-minor] Astrocytoma / metabolism. Cell Line, Tumor. Culture Media. Culture Media, Serum-Free. Enzyme-Linked Immunosorbent Assay. Humans. Isomerism. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Stimulation, Chemical

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] J Neurooncol. 2010 Apr;97(2):309 [20119650.001]
  • (PMID = 17464449.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Culture Media; 0 / Culture Media, Serum-Free; 0 / Gangliosides; 0 / Transforming Growth Factor beta; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


95. Wolff JE, Berrak S, Koontz Webb SE, Zhang M: Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients. J Neurooncol; 2008 May;88(1):57-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
  • Even though past studies have suggested efficacy of nitrosourea drugs in patients with high-grade glioma and temozolomide has recently been shown significantly to be beneficial, no conclusive comparisons between these agents have been published.
  • We performed a survival gain analysis of 364 studies describing 24,193 patients with high-grade glioma treated in 504 cohorts, and compared the effects of drugs.
  • The most frequent diagnoses were glioblastoma multiforme (GBM) (72%) and anaplastic astrocytoma (22%).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Nitrosourea Compounds / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18253699.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0S726V972K / Nimustine; 7BRF0Z81KG / Lomustine; U68WG3173Y / Carmustine
  •  go-up   go-down


96. Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE 2nd, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS: Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer; 2005 Oct 1;104(7):1478-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
  • BACKGROUND: The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG).
  • Ninety-one patients (85%) had recurrent glioblastoma multiforme (GBM) and 16 (15%) had recurrent anaplastic glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16088964.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA096890; United States / NCI NIH HHS / CA / CA11898; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


97. Ritz R, Müller M, Dietz K, Duffner F, Bornemann A, Roser F, Tatagiba M: Hypericin uptake: a prognostic marker for survival in high-grade glioma. J Clin Neurosci; 2008 Jul;15(7):778-83
Hazardous Substances Data Bank. PERYLENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypericin uptake: a prognostic marker for survival in high-grade glioma.
  • Twelve primary human glioma cell cultures were incubated with 20 micromol HY.
  • Three patients suffered from an anaplastic astrocytoma, WHO grade III, nine had a glioblastoma, WHO grade IV.
  • In summary, HY uptake by ex vivo glioblastoma cell cultures seems to be positively associated with survival of patients with malignant glioma.
  • [MeSH-major] Brain Neoplasms / drug therapy. Drug Resistance, Neoplasm / genetics. Glioma / drug therapy. Perylene / analogs & derivatives. Photochemotherapy / methods
  • [MeSH-minor] Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / metabolism. Astrocytoma / physiopathology. Cell Line, Tumor. Cell Proliferation. Disease-Free Survival. Drug Therapy. Female. Fluorescence. Glioblastoma / drug therapy. Glioblastoma / metabolism. Glioblastoma / physiopathology. Humans. Light. Lipoproteins, LDL / metabolism. Male. Microscopy, Fluorescence / methods. Middle Aged. Models, Statistical. Predictive Value of Tests. Prognosis. Radiation-Sensitizing Agents / metabolism. Radiotherapy. Survival Rate

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Neurosci. 2009 Oct;16(10):1381-2 [19595595.001]
  • (PMID = 18394904.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Lipoproteins, LDL; 0 / Radiation-Sensitizing Agents; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


98. Oermann E, Collins BT, Erickson KT, Yu X, Lei S, Suy S, Hanscom HN, Kim J, Park HU, Eldabh A, Kalhorn C, McGrail K, Subramaniam D, Jean WC, Collins SP: CyberKnife enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures. J Hematol Oncol; 2010;3:22
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CyberKnife enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures.
  • Temozolomide-related improvements in high-grade glioma survival have placed a higher premium on optimal radiation therapy delivery.
  • We investigated the safety and efficacy of utilizing highly conformal and precise CyberKnife radiotherapy to enhance conventional radiotherapy in the treatment of high grade glioma.
  • All patients received conventional radiation therapy following tumor resection, with a median dose of 50 Gy (range: 40 - 50.4 Gy).
  • At a median follow-up of 63 months for the anaplastic glioma cohort, the median survival has not been reached and the 4-year survival rate was 71%.
  • CONCLUSION: We utilized fractionated CyberKnife radiotherapy as an adjunct to conventional radiation to improve the targeting accuracy of high-grade glioma radiation treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Glioma / therapy. Radiosurgery

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1313-9 [11728692.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:219-22 [11143252.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):140-6; discussion 146-7 [12493111.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1400-8 [12654453.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):721-6 [14967426.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52 [15001257.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60 [15465203.001]
  • [Cites] Neurosurgery. 2004 Nov;55(5):1138-49 [15509320.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1976 Jul-Aug;1(7-8):627-37 [185169.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] Neurosurgery. 2005 Jun;56(6):1254-61; discussion 1261-3 [15918941.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):892-7 [16458777.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1422-8 [16750317.001]
  • [Cites] Radiat Oncol. 2006;1:46 [17173702.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4127-36 [17827463.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):926-33 [18514784.001]
  • [Cites] Phys Med Biol. 2008 Sep 7;53(17):4697-718 [18695294.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):459-66 [19269895.001]
  • [Cites] J Hematol Oncol. 2009;2:16 [19341478.001]
  • [Cites] Semin Radiat Oncol. 2009 Jul;19(3):179-86 [19464633.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Neurosurg Rev. 2009 Oct;32(4):417-24 [19633875.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S20-7 [20171513.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1635-42 [11896114.001]
  • (PMID = 20534128.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2891601
  •  go-up   go-down


99. Limentani SA, Asher A, Heafner M, Kim JW, Fraser R: A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol; 2005 May;72(3):241-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
  • Two types of chemotherapy used in the treatment of patients with malignant glioma are carboplatin and Gliadel wafer [(3.85% 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)].
  • The purpose of this study was to evaluate combination chemotherapy with Gliadel wafer and carboplatin in patients with high-grade, malignant glioma.
  • Fourteen (88%) patients had glioblastoma multiforme and 2 (12%) had anaplastic astrocytoma.
  • We conclude that administering systemic carboplatin is safe and well tolerated in the postoperative period immediately following resection and implantation of Gliadel wafer for the treatment of malignant glioma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Carboplatin / therapeutic use. Decanoic Acids / therapeutic use. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Polyesters / therapeutic use

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937647.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Drug Implants; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; BG3F62OND5 / Carboplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


100. Waha A, Felsberg J, Hartmann W, von dem Knesebeck A, Mikeska T, Joos S, Wolter M, Koch A, Yan PS, Endl E, Wiestler OD, Reifenberger G, Pietsch T, Waha A: Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res; 2010 Feb 15;70(4):1689-99
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells.
  • Critical tumor suppression pathways in brain tumors have yet to be fully defined.
  • In 83 astrocytic gliomas and 5 glioma cell lines examined, hypermethylation of the MKP-2 promoter was found to occur relatively more frequently in diffuse or anaplastic astrocytomas and secondary glioblastomas relative to primary glioblastomas.
  • Our findings reveal MKP-2 as a common epigenetically silenced gene in glioma, the inactivation of which may play a significant role in glioma development.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Proliferation. Dual-Specificity Phosphatases / genetics. Epigenesis, Genetic / physiology. Glioma / pathology. Mitogen-Activated Protein Kinase Phosphatases / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. DNA Methylation. Down-Regulation / physiology. Female. Gene Expression Regulation, Neoplastic / physiology. Gene Silencing / physiology. Genes, Tumor Suppressor / physiology. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124482.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.- / Mitogen-Activated Protein Kinase Phosphatases; EC 3.1.3.48 / DUSP4 protein, human; EC 3.1.3.48 / Dual-Specificity Phosphatases
  •  go-up   go-down






Advertisement